#359 ‒ How metabolic and immune system dysfunction drive the aging process, the role of NAD, promising interventions, aging clocks, and more | Eric Verdin, M.D.

View the Show Notes Page for This Episode https://peterattiamd.com/ericverdin/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=250804-pod-ericverdin&utm_content=250804-pod-ericverdin-podfeed Become a Member to Receive Exclusive Content https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=250804-pod-ericverdin&utm_content=250804-pod-ericverdin-podfeed Sign Up to Receive Peter's Weekly Newsletter https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=250804-pod-ericverdin&utm_content=250804-pod-ericverdin-podfeed Eric Verdin is a physician-scientist and the CEO of the Buck Institute for Research on Aging whose career has centered on understanding how epigenetics, metabolism, and the immune system influence the aging process. In this episode, Eric traces his scientific journey from studying viruses and histone deacetylases (HDACs) to leading aging research at the Buck Institute, offering insights into how aging impairs immune and nervous system function—including thymic shrinkage, chronic inflammation, and reduced vaccine response—and how these changes impact lifespan. He explores the metabolic underpinnings of aging, such as oxidative stress and insulin and IGF-1 signaling, and he discusses practical tools like zone 2 cardio, ketogenic diets, and GLP-1 drugs. The conversation also covers declining NAD levels with age, the roles of NAD-consuming enzymes such as sirtuins and CD38, and what current NAD-boosting strategies (like NMN, NR, and IV NAD) can and can't accomplish. Eric weighs in on promising longevity interventions including rapamycin, growth hormone for thymic regeneration, and anti-inflammatory therapies, while also examining the promise and limitations of current biological age tests and the potential of combining epigenetic, proteomic, and organ-specific metrics with wearables to guide personalized longevity care. We discuss: Eric's scientific journey from virology to the field of geroscience [2:45]; How dysfunction in the immune system and central nervous system can drive aging throughout the body [5:00]; The role of metabolism and oxidative stress in aging, and why antioxidant strategies have failed to deliver clear benefits [8:45]; Other aspects of metabolism linked to aging: mitochondrial efficiency, fuel utilization, and glucose-modulating drugs [16:30]; How inefficient glucose metabolism drives insulin, IGF-1 signaling, and accelerates aging [21:45]; The metabolic effects of GLP-1 agonists, and the need to move beyond crude metrics like BMI in favor of more precise assessments of metabolic health [27:00]; The case for immune health as a "fifth horseman" [36:00]; How the innate and adaptive immune systems work together to build immune memory [39:45]; Why vaccines lose effectiveness with age: shrinking of the thymus gland and diminished T-cell diversity [44:15]; Exploring growth hormone, thymic regeneration, and the role of exercise in slowing immune aging [48:45]; The challenges of identifying reliable biomarkers for immune function, and the potential of rapamycin analogs to enhance vaccine response in older adults [57:45]; How rapamycin's effects on the immune system vary dramatically by dosage and frequency [1:03:30]; The limitations of mouse models in aging research and the need for cautious interpretation of rapamycin's benefits in humans [1:08:15]; NAD, sirtuins, and aging: scientific promise amid commercial hype [1:15:45]; How CD38 drives age-related NAD decline, influences immune function, and may impact longevity [1:23:45]; How NMN and NR supplementation interact with CD38 and NAD metabolism, and potential risks like homocysteine elevation and one-carbon cycle depletion [1:31:00]; Intravenous NAD: limited evidence and serious risks [1:37:00]; Interleukin-11 (IL-11) as a new target in immune aging, the dual role of chronic inflammation in aging, and the need for better biomarkers to guide interventions [1:43:00]; Biological aging clocks: types of clocks, promise, major limitations, and future outlook [1:48:30]; The potential of proteomics-based aging clocks for detecting organ-specific decline and frailty [2:00:45]; and More. Connect With Peter on Twitter https://twitter.com/PeterAttiaMD, Instagram https://www.instagram.com/peterattiamd/, Facebook https://www.facebook.com/peterattiamd/ and YouTube https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg

Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.

• 0:11Dr. Peter Attia?

  Hey everyone, welcome to the Drive Podcast. I'm your host, Peter Attia. This podcast, my website, and my weekly newsletter all focus on the goal of translating the science of longevity into something accessible for everyone. Our goal is to provide the best content in health and wellness, and we've established a great team of analysts to make this happen. It is extremely important to me to provide all of this content without relying on paid ads. To do this, our work is made entirely possible by our members, and in return, we offer exclusive, member-only content and benefits above and beyond what is available for free. If you want to take your knowledge of this space to the next level, it's our goal to ensure members get back much more than the price of the subscription. If you

• 0:54Dr. Peter Attia?

  want to learn more about the benefits of our premium membership, head over to peterattiamd.com/subscribe.

• 1:04Dr. Peter Attia?

  My guest this week is Dr. Eric Verden. Eric is a physician scientist who spent two decades uncovering how epigenetics, metabolism, and the immune system drive aging, and now serves as the president and CEO of the Buck Institute for Research on Aging. In this episode, we discuss Eric's path from studying viruses and HDax to leading the Buck Institute and focusing on aging research. How aging changes the immune and nervous system, thymus shrinkage, for example, loss of T-cell diversity, chronic inflammation, and weaker vaccine response, and why these changes can ultimately shorten lifespan. Metabolic drivers of aging, oxidative

• 1:43Dr. Peter Attia?

  stress, fuel choice, insulin and IGF-1 signaling, and practical tips on Zone 2 cardio, ketogenic nutrition, and GLP-1 drugs. Why NAD levels fall with age, the role of sirtuins and CD38, what NMN, NR, IVNAD can and can't do, and the importance of stopping NAD loss. Drugs that have the potential to slow aging. Including optimal rapamycin dosing, growth hormone-based thymus regrowth, blocking IL-11 or IL-1, and how these things might compare with, say, exercise, current ways to measure biologic age, and the limits of today's epigenetic clocks,

• 2:26Dr. Peter Attia?

  new proteomic and organ-specific tests, and how combining multiple metrics with wearables may guide personalized longevity care. So, without further delay, I hope you enjoy my conversation with Dr. Eric Verdin.

• 2:44Dr. Peter Attia?

  Eric, thank you so much for coming to Austin. I know it wasn't just to talk to me. I know that half of it was getting you to drive on the track at Cota tomorrow with me, so we're gonna have some fun there.

• 2:54Speaker 01

  My pleasure.

• 2:55Dr. Peter Attia?

  But, as much as I think the two of us could sit here and talk about race cars for the next three hours, I don't think the audience would appreciate it or care for it as much as they will care for what we will talk about, which is your work in geoscience. So maybe give folks a little bit of a sense of what attracted you to this field, and how your journey and background brought you where you are.

• 3:17Speaker 01

  It's a bit of a serendipitous type of story in a way that I'm an MD by training from Belgium. Did my last year of medical school at Harvard, and this just sort of opened my eyes to a whole world. I was the first person in my family to go to college, ending up at Harvard with some of the best teachers, some of the best students, which was just mind-blowing. And I went to medical school wanting to do research. Never had that sort of a doctor fiber, I call it, so really wanted to research. And so after this, finished medical school and came back for directly a postdoc at the Charleston Clinic, working on diabetes and metabolism. So this is where the story gets so curious. Ended up becoming interested in the reason for the etiology of type 1 diabetes,

• 4:00Speaker 01

  and worked on viruses and autoimmunity. This eventually led me to mostly a career in virology, which confuses people. So I spent many years working on a variety of viruses, including HIV and herpes viruses and so on. And through that work, we ended up learning a family of protein called some of the first epigenetic regulators, the HDax. And the H-Dax at the time, that was 1996, we were responsible for the cloning of a whole family of these epigenetic regulators, ended up being important in aging. And starting in around 1995, 1996, my lab slowly shifted towards the study of aging. And to this point today, actually, I only have one last postdoc in the lab who's working on HIV.

• 4:45Speaker 01

  The whole lab is actually focused on epigenetics, immunology, and metabolism, so that the interface between these variables. So in some ways, it's the beauty of an academic career, which I've just followed my interests, sometimes followed the money a little bit in terms of funding. Now, I mean, I have another additional responsibility, which is to lead the Buck Institute for Research on Aging. I have split my time between the lab and some more leadership type of activities.

• 5:12Dr. Peter Attia?

  So you mentioned two things there, metabolism and immunology. Talk a little bit more about how each of those individually contributes to aging. I think most people will intuitively understand it, but talk maybe a little deeper about it.

• 5:26Speaker 01

  Well, first, immunology is central to aging in many respects. I hope we can talk about this later. There is data showing that there are two organs that are rate limiting in terms of your aging, and it's the central nervous system and the immune system. And the reason for this is actually, one could have predicted this based on the fact that both organs are distributed organs. If you think of your immune system, it's located in pretty much throughout the whole organism. And so its activity can influence the well-being or the functioning of every single organ. The same goes for the central nervous system. And there's a recent study coming out, actually, from the lab of Tony Wiskeray, showing that

• 6:10Speaker 01

  those biomarkers that measure aging in those organs appears to be the most predictive of your lifespan. There's also incredible data showing that if you induce a specific lesion in the immune system, for example, in mice model, if you knock out ERCC1, DNA damage repair, only in the bone marrow, so that the whole immune system is affected, you actually induce accelerated aging in the whole organism and senescence in every single organ.

• 6:39Dr. Peter Attia?

  In what model?

• 6:40Speaker 01

  It's been done in two different models in mice. It's been done with the ERCC one mutation. It's also been done by knocking down the major TFM, the major transcription factor for mitochondria. So if you induce mitochondrial dysfunction only in the immune system, you induce secondary senescence in the whole organism.

• 6:56Dr. Peter Attia?

  Do you think that would be true in humans?

• 6:58Speaker 01

  It's a million dollar question. In some way, it's been shown in two different models in mice.

• 7:03Dr. Peter Attia?

  B6?

• 7:04Speaker 01

  I don't remember the exact strain of the mouse, but there is no reason why it should be different, frankly. And it speaks to the importance of the immune system. The second way for the immune system is through chronic inflammation, which is tied cause and effect in the whole aging process. And we can talk about this later as well. I find it fascinating, the whole idea of chronic inflammation, which is induced by the aging process, but itself actually further accelerates aging. So there's really a lot of work that's being conducted in this area. The other one that you were asking is metabolism.

• 7:36Dr. Peter Attia?

  That's a very interesting idea, that two organ systems that are going to be rate limiting in age are the central nervous system and the immune system, both of which are distributed. Where would you put the endothelium in that list as well? The endothelium is also quite distributed across the organism. And do you think that there is an inevitability to basically endothelial damage as a process of aging? Which of course results in the leading cause of death, the atherosclerotic diseases. Do you think of it the same way or do you think of it as different?

• 8:05Speaker 01

  It's not sort of defined as an organ by itself. It's a cell type. I agree with you has incredible importance, especially as it affects the heart and cardiovascular system.

• 8:16Dr. Peter Attia?

  And the brain.

• 8:17Speaker 01

  And the brain. But I think of it as not so much as an organ, but it's more as a principle that maintenance of barrier function, not only in the endothelium, but also in the skin and the blood brain barrier are emerging as key areas to focus on if you want to maximize your longevity.

• 8:36Dr. Peter Attia?

  Yeah, I want to come back to this in great detail, Eric, but let's, for the sake of summary and synthesis, turn over to where you wanted to around metabolism.

• 8:44Speaker 01

  So metabolism is essential to life expectancy for a number of reasons. One of them, I'm convinced, even though that theory has been somewhat discredited, the whole oxidative stress theory of aging, I still think oxygen is one of the major problems associated with the aging process. We have not been able to target the oxidative stress using antioxidant. That has failed. It doesn't mean that the whole oxidative stress theory of aging is not valuable. I think living in an oxidative environment is one of the mechanisms that leads to aging, not the only one. Aging is pleomorphic.

• 9:22Dr. Peter Attia?

  But just to make sure folks understand what you're saying, Eric, you're saying that the generation of free radicals through oxygen, so I don't know how technical we want to get for people, but I think unfortunately we might need to get a little more technical and apologies to those who don't want to go this deep, but we have to talk about kind of what the role of the electrons are in oxygen and why free radicals form and what they do. So maybe we do go a little deeper here and explain what you're saying. It's a very important concept and I think we should probe it.

• 9:50Speaker 01

  I don't know how much, I mean, maybe you'd do a better job at explaining this for the layperson. I mean, oxidative stress is a fact that pretty much the main metabolic reaction are dependent on oxygen, which gives its electron. It's in the so-called respiratory chain. There is leakage of these electrons that are traveling down this respiratory chain, leakage at specific places. You know, if the process was 100% efficient, the whole energy would be transferred from metabolites such as fatty acid, glucose and so on. But it turns out the mechanism is actually leaky. These electrons reacting with oxygen can generate these byproducts called radical oxygen species, which are highly reactive.

• 10:33Dr. Peter Attia?

  Right, so they're not chemically stable the way we think of a normal atom of oxygen.

• 10:38Speaker 01

  No. And so they tend to react with proteins, with fatty acid, and they induce lesions. The importance of this system in terms of protection against it is highlighted by the number of molecular systems that we have that are actually protecting against this.

• 10:53Dr. Peter Attia?

  And we know that as we age, that leakage increases.

• 10:57Speaker 01

  Exactly.

• 10:58Dr. Peter Attia?

  So something about the integrity of the mitochondria and the respiratory electron transport chain degrades as we age, and therefore we see more and more of this leakage. Yeah?

• 11:09Speaker 01

  Yes, absolutely. And so out of this came the whole idea, well, let's just suppress oxidative stress. And there are chemicals, even some as simple as vitamin E, vitamin C, that you could imagine that by chemical knowledge would be predictive to be able to quench these radical oxygen species.

• 11:31Dr. Peter Attia?

  Sorry to just keep interrupting you. We'll play off each other to do this.

• 11:34Speaker 01

  This is great.

• 11:35Dr. Peter Attia?

  So you eat, for example, an antioxidant, and as you said, it neutralizes that reactive oxygen species with its unstable electrons, kind of like you would throw a blanket on a fire that's simmering.

• 11:47Speaker 01

  Exactly, and that was the hope. So when the theory was proposed, a whole industry actually grew up out of this, the whole antioxidants and the antioxidant diet and the vitamins and so on. You can still, by the way, that whole industry is still existing today.

• 12:03Dr. Peter Attia?

  Sure does.

• 12:04Speaker 01

  Now, what happened is that when clinical trials were conducted in this area, they failed. And so people who think relatively simply decided, well, the antioxidant failed, therefore the theory has no validity. I would say not so fast, because it turns out that these radical oxygen species also have important roles. They actually are inducing an inflammatory response, which can be protective. And a good example is during exercise, there is some evidence of activation of oxidative stress during exercise. And if you neutered this, for example, with anti-inflammatory, you probably remember the data showing that anti-inflammatory drug tend to suppress some of the beneficial effect of exercise. It's the same whole idea.

• 12:48Speaker 01

  And so this is one case in which these radical oxygen species can have a protective role and actually a signaling role. So when you suppress it completely with these global nonspecific antioxidant, essentially you're not only killing the Bad guys, but you're also suppressing an important signaling mechanism.

• 13:07Dr. Peter Attia?

  There's another hypothesis that I would offer, which is, is it possible that there's still a net negative to the free radicals? So there might be some benefits, but more negatives. But it could be that the trials were using agents that were simply ineffective. Because the problem is, we don't have a great biomarker for the state of free radicals. So it's sort of like saying, I have a hypothesis that this biological process is bad. I can't measure it really, but I think it's bad. I have a drug that I think will tamp it down. Let's give the drug, the trial failed. Well, do you actually know if it tamped the thing down? We don't even know if we tested the hypothesis, correct? And so those would be kind of two distinct plausibilities.

• 13:51Speaker 01

  I completely agree, and it's quite often the case. I mean, the whole story of vitamin D is a good example.

• 13:56Dr. Peter Attia?

  Absolutely.

• 13:57Speaker 01

  People will tell you, you know, vitamin D doesn't work because they conducted clinical trials, but they didn't fix, they didn't adjust the dose, they didn't measure the levels. So it's a bit the same story. There are markers that you can actually do use in research environment like fibohydroxynonanol or protein carbonylation, which are indirect markers of lipid or protein oxidation.

• 14:20Dr. Peter Attia?

  How efficacious or beneficial, or I guess the word is, how complete are they in the scope of understanding? And have we demonstrated that mega doses of vitamin E or vitamin C will indeed suppress those markers in humans?

• 14:35Speaker 01

  They're not great.

• 14:35Dr. Peter Attia?

  Okay.

• 14:36Speaker 01

  They're not great. I had a colleague at the Buck Institute, Martin Brand, who is one of the leaders of the whole mitochondrial filical bioenergetics, which is the study of how the respiratory chain and energy metabolism happens in mitochondria. And he came up with the idea that he identified many of the sites where these unique radical oxygen species are generated. And he was able to generate specific inhibitors for each of the sites. And was able to show that actually inhibition at some sites was beneficial, while inhibition at other sites was not beneficial. So this project was actually supported by a pharma company. Which eventually decided to drop the program and he's retired, which I think is a great loss because it is a whole program that still needs to be pursued.

• 15:22Dr. Peter Attia?

  So if I'm understanding what you said correctly, Eric, it sounds like there's a much more nuanced view. It's not that free radicals are bad and it's not that free radicals are good. It's like everything in biology, it's the Goldilocks rule. You might need more of it during this circumstance in this part of the body. You might need less of it in this circumstance at this totally different part of the body. And as a result, any strategy that would try to globally suppress it could even if successful in doing it, which we haven't been able to measure, might actually not yield to a favorable outcome.

• 15:56Speaker 01

  Totally correct. I get frustrated by the way that people sort of love to oversimplify or sort of erase whole fields. I suspect we will get to talk about sirtuins because the same thing has happened in the sirtuins. There's a lot of amazing work done and then a few negative results or things not working out. NAD metabolism, same thing. I always tell people, you know, once you get into any field of study and you go deep and you start testing in humans, put on your seatbelt because it's not easy and there are no magic bullets. But I think stopping the study and saying the whole field is BS is really for me not the way to go. We got to dig deeper and eventually, you know, we'll get to that.

• 16:38Dr. Peter Attia?

  Tell me what else within metabolism you think is kind of a hallmark of aging. So we've obviously talked about the central part of metabolism, which is respiration and ATP generation and the leakage that occurs there. And basically, unfortunately, that just appears to be inevitable.

• 16:56Speaker 01

  Yes, we will never stop the oxygen in our environment.

• 16:59Dr. Peter Attia?

  I do like to tell my patients that this is why I kind of harp on them to do a lot of zone two cardio training. So zone two, very specifically by definition, is the canonical exercise you would do to maximize fat oxidation, which of course implies the most efficient use of the mitochondria.

• 17:23Dr. Peter Attia?

  Hypothesis, because I don't think, you know, we don't have proof of this, but the hypothesis is training at that level for specific periods of time throughout the week is a way to improve the health and function of your mitochondria, which would hopefully imply that you're reducing that degradation of function. Do you think there's validity to that, at least first order logic?

• 17:44Speaker 01

  Yeah, I mean, the proof is in the pudding in a way that we know exercising and a combination of exercise is the best anti-aging intervention we have.

• 17:53Dr. Peter Attia?

  But do you think part of it is through that exact mechanism?

• 17:56Speaker 01

  Yes.

• 17:56Dr. Peter Attia?

  Yeah, I mean, that's been my hypothesis, but again, we can't fully glean that in any human clinical trial.

• 18:01Speaker 01

  No, hard to study. And I think your point allows me to sort of address your question. What is it about metabolism that really is so important? I think I'm convinced that it is fuel utilization. You mentioned fatty oxidation versus glycolysis, and I'll add ketosis to this. I think if you think about your metabolism is able to oxidize a number of different substrates, amino acids, fatty acids, glucose, and ketones.

• 18:28Dr. Peter Attia?

  And lactate.

• 18:28Speaker 01

  And lactate.

• 18:29Dr. Peter Attia?

  Yep.

• 18:29Speaker 01

  And every one of those actually burns with different efficiency, both being car aficionado. I think your audience probably knows also that there's different to burn diesel or to burn 100 octane gas. And if you look at that hierarchy, I think ketones are probably the cleanest fuel to burn in terms of, again, byproducts oxidative stress. They seem to be really unique.

• 18:53Dr. Peter Attia?

  Yeah. How would you rank order from cleanest to dirtiest, inclusive of lactate?

• 18:57Speaker 01

  Lactate, I would not be able to put it.

• 18:59Dr. Peter Attia?

  Okay.

• 19:00Speaker 01

  I think it's probably clean.

• 19:01Dr. Peter Attia?

  Yeah, I think my intuition is it is as well.

• 19:03Speaker 01

  The top would be.

• 19:04Dr. Peter Attia?

  Beta hydroxybutyrate.

• 19:05Speaker 01

  Beta hydroxybutyrate. Acetoacetate is present in such low abundance, it's probably not relevant as a fuel source. Then fatty acid, next is worse is actually glucose. And when you think about metabolism and aging, for me, it goes to a lot of the data that has emerged from the ITP, for example, Intervention Testing Program.

• 19:26Dr. Peter Attia?

  Rich Miller has been on several times.

• 19:28Speaker 01

  I watched your recent podcast with Rich and others. One of the remarkable thing when you look at. The drugs that have a seven or whatever, 10 drugs that have emerged out of 80, they are really targeting glucose metabolism via completely different mechanism. Think about acarbose, which is blocking absorption of glucose. Think about the canaglyphosin, which is targeting a protein that has nothing to do links to glucose reabsorption in the kidney. Think about metformin, which is, you know.

• 19:57Dr. Peter Attia?

  But metformin failed.

• 19:58Speaker 01

  Yeah, it failed, but it seems to be having very powerful effect. Well, it did not fail, actually.

• 20:03Dr. Peter Attia?

  It failed unless it was paired with rapamycin.

• 20:05Speaker 01

  Yes, and in monkeys, there's a study coming out that showed that it actually had an effect on lifespan.

• 20:10Dr. Peter Attia?

  And do you think rapamycin has any impact on glucose metabolism favorably?

• 20:14Speaker 01

  Generally, actually, this is, rapamycin is the exception to this because it seems to be having, it's not indifferent. It has been claimed to be having an effect on insulin sensitivity.

• 20:25Dr. Peter Attia?

  Although I'm not clear if that's true at the doses, but anyway, yeah, we can come back to that.

• 20:29Speaker 01

  I've taken rapamycin. I have not seen any effect on my blood sugar. Think about acarbose, canaglyphosin, metformin, and now the GLP-1 agonist, which I predict will emerge as geroprotectors in the future. So I think that's really speaks to an important aspect, which is fuel utilization and how, whether you're burning a clean fuel, whether you're burning a dirty fuel. We've put, for example, mice on a pure fat diet. These mice never saw a carbohydrate during their life and they lived longer, which I thought was actually quite interesting.

• 21:06Dr. Peter Attia?

  It is interesting, Eric, because a lot of the mouse literature, I think people don't read the fine print very closely. They don't notice that the typical thing you'll see is these mice were fed a high fat diet to induce obesity so that we could test drug A, B, or C against obesity. In those studies, it's not just a high fat diet, it's a high fat, high sugar diet. So they're making some insanely hyper palatable, the closest I can come up with is they're making a donut.

• 21:34Speaker 01

  Yes.

• 21:35Dr. Peter Attia?

  Right. It's a fried dough, sugar food. So they're making basically donuts for these monkeys. And that's different than saying it's a high fat thing. So yeah, I think it's important to point out because high fat minus the sugar might not be the same issue. Right?

• 21:50Speaker 01

  I agree.

• 21:50Dr. Peter Attia?

  At least in that model. So what do you think it is about glucose metabolism that leads to this? Because for all intents and purposes, let's just go through the metabolic pathways. So glucose, six carbons. It gets broken down into pyruvate. You get two pyruvates for one glucose, right? And then pyruvate, let's just assume we're doing this under aerobic conditions. So we're not in a rush. We're going to take those pyruvates. Do they turn into acetyl CoAs? I can't even remember to then enter the.

• 22:22Speaker 01

  It's actually one pyruvate and that enters the mitochondria and becomes acetyl CoA.

• 22:26Dr. Peter Attia?

  Acetyl CoA, okay, okay. So what is it about that process that is not as efficient as when you are cleaving off carbons from a free fatty acid and those carbons are turning directly into, I think, just a straight acetyl CoA and then entering the Krebs cycle. I mean, it's a very subtle difference. Why is one so much more inefficient?

• 22:47Speaker 01

  You mean, why is there more calories per fatty acid now?

• 22:51Dr. Peter Attia?

  No, no, no, no, no. That can be explained by the story geometry. Why is one quote unquote dirtier?

• 22:55Speaker 01

  Okay. Obviously, this is a really complicated question. So I don't know that I would be able to really tell you purely as fuels, whether there is a difference. I think the biggest difference is in terms of the whole mechanism that they elicit. And when we think about glucose, I don't think necessarily of it, if you were to study it in a tissue culture dish, that one would be more toxic than the other. I don't think there's any evidence for this. But glucose, and particularly the form of glucose that we have not evolved to actually be exposed to, which is all the wheat products, this fast form of glucose, elicits insulin secretion. And I think insulin and IGF-1, particularly insulin, is the culprit in this whole process.

• 23:41Dr. Peter Attia?

  So you're not saying that one mole of glucose, one mole of free fatty acid, we know there's a difference in ATP generation, but you're not saying that there's a different, assuming they're both going through the mitochondria, you're not saying there's a difference in free radical formation mole per mole? Or are you saying that it's this way? There's another way to explain it, which is per mole of ATP, you need to run so much more glucose through that of course you're going to get more leakage?

• 24:09Speaker 01

  The key difference is that the glucose is generating ATP not only via acetylcholine pyruvate, but is also generating ATP in the intracellular plasmic components.

• 24:20Dr. Peter Attia?

  Right.

• 24:21Speaker 01

  The fatty acids do not generate any. So I suspect that there might be a difference in terms of the amount of free radical that are generated. There is evidence, but I would not be able to cite you the paper, that one burns more cleanly than the other. And I suspect it's partly the cytoplasmic component of glucose. It's also less efficient in terms of the amount of energy that's being generated per gram of fatty acid or per mole of fatty acid versus per mole of glucose.

• 24:47Dr. Peter Attia?

  And then going back to the insulin IGF component here, what role do you think they're playing?

• 24:53Speaker 01

  Critical, because epidemiologically and through studies, we know that the insulin response to your glucose. So if you do a lot of sports, I'm not a proponent of the low carbohydrate or no carbohydrate diet, because there's very little evidence that those diets are actually beneficial. I gave you the example of a ketogenic diet, which we did experimentally, but these are not practical diet for anyone.

• 25:17Dr. Peter Attia?

  Just because of the challenge in avoiding carbohydrates in the standard world we live in?

• 25:23Speaker 01

  Yes, both socially, palatably. I mean, there's so many reasons. I went on a ketogenic diet. And from what I remember, I think you went to.

• 25:31Dr. Peter Attia?

  I did for three years. I was on a ketogenic diet, so we should compare notes. I want to hear your experience, and then I want to ask you a couple of questions about it.

• 25:38Speaker 01

  It was very hard.

• 25:39Dr. Peter Attia?

  How long did you do it?

• 25:40Speaker 01

  For a couple of years. And I did not feel super healthy, which is very kind of interesting. I found it socially isolating. We've worked actually to remedy. We can talk about this later on novel keto.

• 25:53Dr. Peter Attia?

  Like a keto nester?

• 25:54Speaker 01

  Keto nester, exactly, of beta hydroxybutyrate. So going back to the role of insulin, there is a lot happening and that's been documented that the intensity. First, your average glucose plays a role, average blood glucose, this is measured by hemoglobin A1C in a whole series of complication cardiovascular, as you know. But perhaps more important is the intensity of your peaks. And I think the intensity of the peaks of insulin is a reflection of your glucose intake, fast absorbing glucose. And that's the reason why we advocate, I advocate people to go on a CGM, continuous glucose monitor and to really learn to understand what spikes them.

• 26:37Speaker 01

  The whole idea is to mitigate these peaks of insulin secretion.

• 26:41Dr. Peter Attia?

  I'm just going to play this for all of our patients. We have this discussion with every one of our patients, so it'll be nice to just play this video and let you do the talking.

• 26:49Speaker 01

  The whole idea there is to, again, mitigate these peaks and either dietarily or, for example, the GLP-1 agonists are playing a role in this as well.

• 27:01Dr. Peter Attia?

  Let's talk about this because there is, at least for me, a great deal of confusion around this point. Now, we understand today the role that the gut plays in metabolism. And we understand that a lot of it is transduced through GLP-1. So endogenous production of GLP-1, according to Ralph DeFranzo, the world's authority on this, is what's driving 80% of beta cell activity with respect to insulin. And therefore, when we have insulin resistance, the GLP-1 we're making is insufficient to generate the insulin that's required to manage the glucose. Makes sense if that's the case, that giving exogenous GLP-1, you take a shot of terzepatide or semaglutide,

• 27:45Dr. Peter Attia?

  you're going to put more GLP-1 in the system, you're going to overcome the resistance at the beta cell, you make more insulin, you now have better glucose control, everybody wins. Now, it's not clear that that has anything to do with the weight side of it. That's a separate issue and I want to actually talk about that because there are two very interesting theories as to why these things cause weight loss. But, point here is, wouldn't you expect to see higher levels of insulin? In someone taking a GLP-1 agonist to achieve that better glycemic control?

• 28:17Speaker 01

  Yes, and that's not what you see. And I don't have an answer for this. I've seen the same thing, including personally, I've been experimenting with tuzapateide. My insulin is five now, which is lowest that you can possibly get it. There was a part of me that was worried that I was going to go against my own whole theory about.

• 28:36Dr. Peter Attia?

  Have you checked postprandially? Have you done an oral glucose tolerance test? Because that might be something to do to see what is happening to postprandial insulin, along with postprandial glucose, which of course will be better.

• 28:47Speaker 01

  No, I haven't.

• 28:48Dr. Peter Attia?

  That would be an interesting test to do, yeah.

• 28:50Speaker 01

  I've worn a CGM. My A1C has gone from 5.4, 5.5 to 5.0. And my insulin is down to 5.0 as well, so.

• 29:01Dr. Peter Attia?

  And did you lose any weight?

• 29:02Speaker 01

  I lost a little bit of weight, not a huge amount, six or seven pounds, which was never the goal to start with. And no loss of muscle mass, which actually is the big boogaboo that people will have you fear. No loss of muscle mass if you are exercising. So for me, it's an experiment. I haven't decided this is something I'm going to continue, but I just wanted to really experiment for myself to try to see, okay, what is this drug really doing? And it's been nothing short of remarkable, I think, in some way. One of the most surprising has been for me, this feeling of satiety. You hear about satiety. I was never in my whole life, the type of person that felt full. I could always eat more. And all of a sudden, after about two weeks on this, I just looked at my plate, I says, I'm full. And I heard myself saying this, and I just

• 29:47Speaker 01

  felt like, well, this is really completely different. And for me, you know, the reason why I'm excited about these drugs is, and by the way, this is not an endorsement, this is something to.

• 29:58Dr. Peter Attia?

  Yeah, yeah, this is self experimentation.

• 29:59Speaker 01

  Self experimentation, which is a long part of the tradition of our field. The whole idea is really, the thinking was, one of the biggest advance in longevity medicine is the idea that a range is meaningless. And as a practicing physician, you know this. I went to medical school and we were told that your blood pressure has to be 1/3. Over ninety, that was still the normal range. So you could be one twenty eight over eighty eight and you were still considered normal. The same thing, I went to see my personal physician and told him, my blood sugar is creeping up every year that I'm doing it. And now it's ninety six fasting blood sugar and I'm worried because soon I'm going to be

• 30:39Dr. Peter Attia?

  And he said, it's below a hundred. It's okay.

• 30:41Speaker 01

  Tell me you're normal. Don't worry. And I told him, I said, what is normal? And I think this really is where I think longevity medicine is going to make an important impact. It's really sort of revisiting.

• 30:51Dr. Peter Attia?

  I can't tell you how many times I've had this argument with people about glucose. And here's the funny thing, we have the literature. In other words, we have literature in non-diabetics.

• 31:01Speaker 01

  Your A1C.

• 31:02Dr. Peter Attia?

  That says the lower the A1C, the lower the all cause mortality. It's a monotonic reduction that knows no lower limit.

• 31:11Speaker 01

  I'm with you.

• 31:12Dr. Peter Attia?

  So we say that up to five point six is normal. And if you're at five point six, you're fine, but five point five is better than five point six and five point four is better than five point five. And five is better than five point four and four point eight is better than five point one.

• 31:25Speaker 01

  I'm not there yet.

• 31:26Dr. Peter Attia?

  Yeah, yeah. But my point is, I also find it, I don't know what the word is, maybe sad. I find it sad that we've simplified this problem in an effort to communicate, but have lost the essence of where is lower better? Cause it's not always true in biology. When you look at TSH, for example, when you look at thyroid hormone, much more narrow band in which we would say there's optimal. If it's too low or too high, it's problematic. But it turns out that when it comes to average blood glucose in a non-type one diabetic or someone who's taking insulin, under natural physiologic circumstances, it's just better to be lower. And as you age, it just keeps creeping up.

• 32:03Speaker 01

  Same thing for blood pressure.

• 32:04Dr. Peter Attia?

  Yes.

• 32:05Speaker 01

  They're revisiting the number every five years in terms of making it lower. I think if your blood pressure is a one oh five over sixty five, you're better off than if you're one fifteen over seventy five.

• 32:16Dr. Peter Attia?

  Provided you're not symptomatic, lower is always better.

• 32:19Speaker 01

  You know, I'm frustrated, but I'm also excited by the fact that this is now becoming the norm in a whole new field of physicians who are more aware of actually what is health. And the same for your weight. We know that that's the thing that is really interesting in the whole aging field is this idea that everything is a J curve. So there is a sweet spot where you want to be. And quite often it's broad enough that you can maneuver this in a way to optimize people's health.

• 32:45Dr. Peter Attia?

  What do you think is the relationship between, I mean, body weight is so crude, but maybe we can even talk about it through adiposity, body fat and longevity, once correcting for metabolic health? So it's obvious that so much of the relationship we see between body fat and poor health is really just a proxy for something that's harder to measure, which is metabolic health. It's very easy to measure body fat and we estimate body fat from BMI. And so that's why we have all these population data from BMI. But if you have the luxury of working with actual patients, I couldn't tell you the BMI of one person I take care of, but I know everybody's body fat, everybody's visceral fat and everybody's oral glucose tolerance tests. We know what we know and we know what matters.

• 33:26Dr. Peter Attia?

  Are you convinced that adiposity per se is problematic? Or do you believe that a person can have excess body fat, but be metabolically healthy and confer the same longevity benefit as a metabolically healthy lean person?

• 33:44Speaker 01

  We know there are people who are considered overweight, who are metabolically healthy.

• 33:49Dr. Peter Attia?

  Yes. Easily 20% in my experience.

• 33:52Speaker 01

  Yes. And these are facts. No one can dispute them. You can be overweight and metabolically healthy. What I worry about is the long-term effect.

• 34:01Dr. Peter Attia?

  Do you mean from an orthopedic perspective, with the other complications that come from excess weight? Or are you saying that they're basically increasing their probability of eventually going off the metabolic slide?

• 34:11Speaker 01

  Both. Honestly, I don't know what the data says, but my worry would be that you might be metabolically looking healthy when you're 40, but if you sustain this for 20 years, clearly visceral fat.

• 34:25Dr. Peter Attia?

  Yep, different category.

• 34:26Speaker 01

  Is highly predictive of everything. The other thing I'll say also, the BMI itself is that my BMI is at the border of being overweight.

• 34:33Dr. Peter Attia?

  I am overweight by BMI, I think. I'm four pounds. If I lost four pounds, I would get down to a BMI of 25.

• 34:39Speaker 01

  And I have 11% body fat. So I don't worry about it because I know all in all, I'm metabolically healthy. My numbers are good and all this. So in some way.

• 34:49Dr. Peter Attia?

  It's not a particularly helpful, I mean, it serves its purpose at the population level, but it can't be used to make a decision about an individual. Individual at all.

• 34:55Speaker 01

  Exactly, but it can also sometimes become a confounding variables. And when people do studies and they use these numbers and they make predictions or they draw conclusions that are really not based on the fact that high BMI fraction of the population is heterogeneous in terms of metabolic health. So my colleagues at the Buck, Nathan Price and Lee Hood have actually published a paper.

• 35:17Dr. Peter Attia?

  Wait, I didn't realize they were at the Buck.

• 35:19Speaker 01

  Yeah, both of them.

• 35:20Dr. Peter Attia?

  They were up in Seattle before, weren't they?

• 35:22Speaker 01

  Yes, we recruited both of them actually in the last two years.

• 35:25Dr. Peter Attia?

  Oh, congratulations.

• 35:26Speaker 01

  Yeah, thank you. I think this is transformative for us.

• 35:28Dr. Peter Attia?

  Fantastic guys.

• 35:29Speaker 01

  Really exciting. Lee is still partially in Seattle, so he's partially at the Buck. We've established a collaboration with Phenom Health and Nathan was at Thorn and still a CSO at Thorn, but faculty member at the Buck. And they're really helping us to do something really exciting along these lines. For example, they had a paper describing this BMI, but biochemical BMI based on biological markers that essentially assess your metabolic status. So I think that those tools are available and it's a question of educating the physicians.

• 36:01Dr. Peter Attia?

  And do you know what makes up that biological BMI?

• 36:04Speaker 01

  No, I'll give you the paper.

• 36:07Dr. Peter Attia?

  Okay, we spent a little more time on metabolism than we did immune health and the immune system overall. I'd actually like to go back and talk about it a little bit more. I think, again, the listeners of this podcast are very familiar with the metabolic stuff. We haven't had as many discussions on the immune system. Talked about it at length with respect to cancer. I had Steve Rosenberg on a few years ago. That was a fantastic discussion explaining the role of the immune system in cancer, which I think we're going to have to talk about here because I certainly feel convinced that a big part of why cancer incidence goes up exponentially with age is the declining immune system, not just the accumulation of mutations, although I imagine they both play a role. But I

• 36:49Dr. Peter Attia?

  will tell you something else, Eric, which is, you know, I wrote a book a couple of years ago about this space. And in the book, I talk about these things called the four horsemen. And I describe them as the four things that are basically coming for us all. If you manage to outlive youth, this is not to diminish the role of trauma. And other things that are deadly. But for many people living in OECD nations, it's going to come down to ASCVD, cancer, dementing and neurodegenerative diseases and metabolic diseases. And people often say, Peter, is there anything you wish you'd written in the book that if you go back in time, you would do? And I say, yeah, there are probably many things if I thought about it, but the first thing that jumps out is, I really should have added a fifth horseman, and that is immune health.

• 37:30Dr. Peter Attia?

  And the types of infections that ravage people in old age that a young person would laugh at.

• 37:38Speaker 01

  Thank you for bringing this up. Immunology and aging have been not really mixing very well. One problem is that immunology is an extremely complex and advanced field, along with neuroscience, one of the most complex. So when you go to an aging meeting, there is no one talking about immunology. You go to immunology meeting, there are very few people talking about aging. We try to navigate, even the nomenclature is being used differently. People in immunology talk about immunosenescence, meaning aging of the immune system. They don't mean senescence the way we talk about it in the aging field. So that yields all kinds of crazy communication problems.

• 38:14Dr. Peter Attia?

  Yeah, because if you're in the aging field, then you hear immunosenescence, you think of sasps and things that are being secreted by T cells.

• 38:20Speaker 01

  It just means aging of the immune system. Now, the reason why I think this is a tragic failing for both field is what happened during COVID became obvious that your risk of infection was not linked to your age. The virus infected everyone across, but the outcome could be completely different with eighty-four excess, eighty-four fold excess mortality if you were above seventy-five, eighty-four fold. Now, when this happened, and we can go in terms of trying to understand why did this happen? What are the reasons for this? I went and started to look at the literature. Influenza, it's exactly the same thing. RSV, same thing. So all of these viruses that you can contract in later years will kill you with really significant rates.

• 39:06Speaker 01

  Influenza, I think thirty thousand people die every year from influenza. The mortality in terms of COVID was really highly segregated into the older part of the population. Or in that part of the population that showed accelerated aging, obesity and so on.

• 39:21Dr. Peter Attia?

  Do you think that most of the mortality, any time we saw a gap in mortality, whether it was young versus old, whether it was obese versus non-obese, diabetic versus non-diabetic, any time you looked at that, you saw a difference in mortality? Do you believe that it was always a difference in immune function? I mean, with young versus old, it's very obvious, but do you think that was also true in the other comorbidities?

• 39:43Speaker 01

  I would say so.

• 39:44Dr. Peter Attia?

  Yeah.

• 39:45Speaker 01

  And it comes from two reasons. One is there are two broad immune systems, what we call the innate and the adaptive immune system. I don't know if you want me to-

• 39:54Dr. Peter Attia?

  I would. I actually was gonna say, I think it is worth going full bore on this. I think it is time for people to roll up their sleeves and understand arguably the most interesting system in the human body. I am biased. I spent two years at the NCI doing immunology, but I think this is such an interesting field.

• 40:12Speaker 01

  Our immune system is built to recognize foreign elements. That's really is why it evolved. It has two lines of defense against microbes, bacteria, viruses, fungi, all of those. We are constantly bombarded by those. It is actually amazing because, I mean, the evidence of this is if your immune system doesn't function, the bubble-

• 40:33Dr. Peter Attia?

  It's incompatible with life.

• 40:34Speaker 01

  It's incompatible with life. So we are colonized with bacteria in and out, and our skin's everywhere. So we constantly respond to them in an appropriate manner.

• 40:43Dr. Peter Attia?

  And we survive everything, including disruptions to the barriers.

• 40:47Speaker 01

  Absolutely, absolutely. So we have two lines of defense in the immune system. First, the so-called innate immune system, which is your macrophages, your dendritic cells. But also, pretty much every cell has a whole series of mechanisms that are not pathogen-specific. That is, they will recognize an intruder, be it a virus, be it fungi, be it bacteria, and it will activate a first line of defense. Those line of defenses are nonspecific, and therefore they're less effective.

• 41:19Speaker 01

  And they give time to the so-called adaptive immune system, which is the second part, which is made up of T cells and B cells. And both of those cells have a highly selective defense mechanism. The B cells make antibodies, which will go recognize a bacteria or a fungus or a virus, and the T cells, which are able to actually kill the infected itself. So it will recognize when a cell is colonized by a foreign pathogen and will kill it. So the time course of these is that once you encounter a pathogen, you will be activate your innate immune response. Typically, it can be fever. It can be all kinds of symptoms, but activation of this defense.

• 42:03Speaker 01

  And this gives the whole organism a couple of weeks to actually build the defense for the specifically recognized this organism.

• 42:10Dr. Peter Attia?

  Let's talk a little bit about memory within that system.

• 42:13Speaker 01

  So the innate immune system does not really have a true memory. It will always react in the same way, no matter how many times.

• 42:20Dr. Peter Attia?

  If your kids are ping ponging the same respiratory virus at you from school, your innate immune system has the same playbook. Fever, you're going to get red.

• 42:31Speaker 01

  Inflammation.

• 42:31Dr. Peter Attia?

  Yeah, you're going to get sore.

• 42:32Speaker 01

  Yes.

• 42:33Dr. Peter Attia?

  All of those things are going to happen regardless.

• 42:35Speaker 01

  Exactly, yeah. And that's in contrast to the adaptive immune system because once the initial response has been generated, either via an infection or a vaccination, this is what a vaccination is. It presents you with a given fraction or the whole virus or a part of it. Your body will mount a response and this will lead to the amplification of a subset of cells that are selective. So think about your T cells or your B cells. None of them are the same. We have a process by which we generate so-called diversity, which is billions of different forms of antibodies or T cell receptors that are recognizing in principle, every chemical structure, every protein from a microorganism.

• 43:20Speaker 01

  Now, what happens during the initial encounter, either being a vaccination or an infection, is those B cells or those T cells That have a receptor that is able to recognize the pathogen will become amplified. And they will churn out large amount of the antibody or the T cell clones. Once the job has been done, they will contract, but it will not contract back down to the same level. They will become what we call memory T cells and memory B cells. So that if you encounter the same antigen in the future, the reactivation process is shortened.

• 43:59Speaker 01

  The maturation happens faster. So eventually the whole idea of the vaccination is to sort of get yourself ready with a subset of memory T cell clones or B cell clones. That once the true virus will come, you will be able to mount a response within a few days or up to a week. And so that's how vaccination works. Now, what's interesting during aging is, and people are not aware of this. If you're above seventy, most vaccinations do not work. So people then will ask, they actually, your immune system has aged and your vaccination rate really decreases very strongly. From what I remember, this might be different in different populations, but vaccination rate success is close to thirty percent. If you're above seventy.

• 44:43Dr. Peter Attia?

  During COVID, what was the risk reduction for a person over seventy five who was vaccinated versus not vaccinated?

• 44:52Speaker 01

  Oh, it was almost complete reversal of the effect in terms of the protection.

• 44:57Dr. Peter Attia?

  Meaning it was highly, highly protective.

• 44:59Speaker 01

  Yeah, it was protective.

• 45:00Dr. Peter Attia?

  So how do we reconcile those two facts?

• 45:02Speaker 01

  That's true. To be honest, I don't know how this has been studied. I would be happy to read about this.

• 45:09Dr. Peter Attia?

  Because the COVID vaccine seems to have had a remarkable risk reduction in very old people. Didn't seem to have an impressive risk reduction in younger people. Because the absolute risk was so low, it didn't seem to matter that much. But boy, did it matter in older people.

• 45:25Speaker 01

  But did it matter at the population level or at the individual level? This is what I'm not sure about.

• 45:31Dr. Peter Attia?

  I certainly don't want to go on record saying something, I think we can find the answer and put it in the show notes. My recollection, which could be wrong. Is that the older a person got, the greater the benefit they got from COVID vaccines with respect to mortality? So I guess the question is, let's maybe talk about other vaccines. Is that not the case with influenza? Is that not the case with pneumococcus or any of the other vaccines that are used primarily in older adults?

• 46:01Speaker 01

  In general, and I'm not a vaccine specialist, but the thinking is that there's a dramatic decrease in the efficiency of vaccination against influenza, against RSV, against all of those as you age. The thinking then is, how does it work at the population level? And this is where the whole concept of herd immunity works, is that if you limit the spread of the infection in a family, for example, you're much less likely to infect grandpa.

• 46:28Dr. Peter Attia?

  I see.

• 46:29Speaker 01

  So that's been my understanding of how most of these viruses, these vaccines work.

• 46:34Dr. Peter Attia?

  Yeah, I'm asking a different question. That's an important question. I guess I was asking, obviously, they didn't probably do a randomized control trial, so you've got all these confounders in it, but I wonder if they just looked at all comers to the hospital vaccinated versus non, let's try to control for all the confounders. If the hazard ratio is 1.2, it means nothing, or 0.8, but if the hazard ratio was 0.2 or 8, you'd say even with the confounders, there must be some high degree of protection that came from that. So anyway, I'm sure someone listening to this knows the answer to that. We'll try to find the answer and put it in the show notes, but let's go back to the why. Why is it that as a person ages, they're less likely to respond to a vaccination?

• 47:19Dr. Peter Attia?

  Is it because A, their immune system, the adaptive immune system, is less able to recognize the foreign pathogen and build up a high enough reserve of T cells and B cells that will respond? Or is it B, that they can do that, but the ability for those cells to stay in a memory state and be reactivated is somehow impaired?

• 47:44Speaker 01

  I think it's both, as in everything in aging. But there's one aspect which is really unique, at least in terms of T cell, which are really instrumental in terms of most vaccine response, is the fact that these T cells are generated, the diversity of the T cells is generated by the thymus. And the thymus, a small organ behind the sternum.

• 48:07Dr. Peter Attia?

  How big is your thymus and my thymus right now?

• 48:10Speaker 01

  I'm 68, so it's probably very, very embryonic and it's probably not much left. After age 50, in most people, you find it very small.

• 48:19Dr. Peter Attia?

  Whereas when you're young, it's actually, you can see it on an imaging study. And I would imagine if you and I had a CT scan of the chest, you'd barely be able to pick it up.

• 48:27Speaker 01

  Exactly, and it's replaced by fat, actually, in most people as you age. Although there is some somewhat controversial evidence that there might still be some clones that can be reactivated, even in older people. And human growth hormone, as you know, is one of the interventions that has been shown to actually re-induce thymogenesis.

• 48:47Dr. Peter Attia?

  So let's talk about that a little bit. Are you referring to that Fahey paper from about seven or eight years ago that looked at growth hormone with metformin and DHEA or something like that?

• 48:57Speaker 01

  That's one, but that Fahey paper was actually inspired by work of a colleague of mine when I was at the Gladstone Institute, who did this, actually Mike McKeown and colleagues, did this in patients with HIV, who were chronically infected with HIV, where they lose a lot of their CD4 T cells. And there was an interest. So there's a big lesion initially in infection. And there was an attempt to actually try to see if you could regenerate these populations, to bring them back to a normal. Because even though we had great drugs against HIV, they could not bring those patients back to normal. There was a remaining original insult.

• 49:37Speaker 01

  So they did a trial with human growth hormone that were able to show some degree of thymogenesis and increase in naive T cells in these patients. And I believe the Fahey trial actually tried to reproduce this. I think there's a second Fahey trial that is ongoing, but I haven't seen the results.

• 49:57Dr. Peter Attia?

  Yeah, I mean, the first one was, I don't remember the results. The cocktail was a little suspect.

• 50:03Speaker 01

  I agree.

• 50:04Dr. Peter Attia?

  So the GH made sense, if that's your hypothesis. I believe, I've never spoken with Greg, but I believe reading the trial. The metformin, which was really given at a homeopathic useless dose, I think it was only given at 500, so apologies if it wasn't, but I think it was only given at 500, was meant to offset the glucose metabolism disturbances of GH. Do you remember why the DHEA was given?

• 50:28Speaker 01

  No.

• 50:29Dr. Peter Attia?

  There was some reason for it that made sense on paper, but didn't make sense physiologically. Now, the more important question is, my take on that trial was it was a single active agent, which was growth hormone. Like, I don't think DHEA does anything. I don't think 500 metformin does anything. So the question is, and it was a very small trial, and I think it was open label.

• 50:48Speaker 01

  I have significant problem with the readout of that trial.

• 50:51Dr. Peter Attia?

  So that's what I wanted to ask you about. Remind me of the readout.

• 50:54Speaker 01

  The readout was one of the clocks.

• 50:57Dr. Peter Attia?

  Ah, that's right. This was, Steve Horvath was the other author on that paper.

• 51:01Speaker 01

  Exactly. And actually, this whole story sort of pushed us into a whole project that we've published on, on what we call entry and clock. Because there was in the experiment, in the patients, they indeed observed some increase in the fraction of naive T cells, which tells you and me that something worked. The fraction of naive T cells increased with respect to the memory T cells. The naive T cells are the ones that are generated in the timers. They're naive because they have never met their cognate antigen, and they sit there waiting for something to happen. So the whole idea of treating with human growth hormone was to induce time genesis and to restore the pool of these naive T cells. So I think to some degree, it worked at low level. Then they used the clock on the whole blood.

• 51:46Speaker 01

  And my worry, when I saw the paper, which is a worry that actually existed, predated this, was also a worry when people were using telomere length, is the idea, when you sample the blood, as an immunologist, I know this is a highly dynamic organ. Think about the blood as an organ. We enumerate at this point today with the best technology, more than 500 different populations of cells in the blood. Suppose that these cells vary in response to any intervention, and that these cells individually have a different epigenetic age. You would have the impression That you are rejuvenating, which was the claim of that FAHE paper that they had rejuvenated people. But in effect, what you would do is simply change.

• 52:31Dr. Peter Attia?

  Yeah, it's like you're on a sine wave that goes like this. And you take two sample points, they could be here, they could be here, they could be here. And by the way, as you probably know, Matt Cabreland has famously purchased, I think, four or five of the commercially available aging clocks. He bought them in duplicate and did all of them, sampled them all simultaneously. Two of this, two of this, two of this, two of this simultaneously, take 10 samples. And not only do all the clocks disagree with each other, but even within the same clock, there was disagreement, significant disagreement. So, yeah, I mean, I want to actually come back and talk about clocks in some detail, but given that that study was done years ago with an older clock, I think the clock part of it is not even remotely interesting.

• 53:16Dr. Peter Attia?

  I think the more interesting question is, was there genuine thymic regeneration? If so, how do we reconcile a very pressing and vexing question within geoscience, which is the role of growth hormone? So I've never taken growth hormone, I've never, I shouldn't say I've never prescribed it, I've prescribed it in very rare circumstances for injury healing. But I've never prescribed it for quote unquote longevity benefits, but a lot of people are out there doing so. And as such, I've had lots of patients who come to my practice who have been taking or are on growth hormone. And I will say this, to a person, every single one of them has said, I feel so much better when I take growth hormone than when I do not. I mean, across the board, 100%.

• 54:00Dr. Peter Attia?

  And I can't actually point to evidence that tells them it's bad to take. I can just say it doesn't make sense to take if our goal is to reduce the risk of cancer and if our goal is to slow the aging process. So what is your take on that? Just your intuition, or is there any data you're aware of that would lead one to think that, well, maybe we could pulse a little bit of growth hormone here and there if we get some thymic regeneration? We don't have to be on it all the time. I mean, how would you think about that?

• 54:29Speaker 01

  I do worry about it. I'm not a specialist on growth hormone itself. It induces diabetes, it induces glucose intolerance. So from that angle, I do worry about what it would do chronically, especially in someone young. It's a bit like increasing your protein intake. There's clear evidence that increasing your protein intake, especially as you age, becomes beneficial. And the people who have higher protein intake actually do better in terms of muscle mass and so on. So in someone who is 65 to 70, who is starting to feel the effect of manifest some form of sarcopenia, there might be a benefit for that person to actually increase muscular mass and all the benefits with this,

• 55:14Speaker 01

  especially if it's not done continuously.

• 55:16Dr. Peter Attia?

  I mean, I would argue there's no doubt that there's benefits, but you're going to get far more efficacy from testosterone or anabolic steroids when it comes to mitigating sarcopenia. Growth hormone actually is not remarkable at inducing muscle mass. It's nowhere near as effective as testosterone. It's more effective at eliciting fat loss. But I wonder if there's something that goes beyond that. Because I think when people tell me they feel better on it, I think they're talking about less aches and pains. Joints just feel better. I don't think anybody's saying they feel better because their thymus is more plump. But I wonder, that to me would be a reason to potentially consider a schedule, an intermittent schedule of something. If it's, again, going back to my macro thesis here,

• 56:01Dr. Peter Attia?

  which is, I've been harping on these four horsemen, four horsemen. Well, if we introduce a fifth horseman, what is the strategy? Because I can give you chapter and verse the strategy for how you will mitigate heart disease, cancer, all of these other conditions. What is our strategy for mitigating immune decline?

• 56:19Speaker 01

  I would say the same as a strategy that would mitigate decline in every other organ. There's clear evidence that the effect of exercise on immunology is the same as in every single.

• 56:29Dr. Peter Attia?

  So I'm not familiar with it. So tell me a little bit about that. I don't know specifically how exercise impacts the immune system.

• 56:36Speaker 01

  I cannot speak to specific papers. Clearly, there is evidence that people who exercise actually respond to infection better, respond to vaccination better. So that's all been documented.

• 56:46Dr. Peter Attia?

  I see.

• 56:47Speaker 01

  I cannot speak to specific studies.

• 56:48Dr. Peter Attia?

  Do you have a sense of mechanistically why that's the case?

• 56:51Speaker 01

  It is so complex. I would say I would not be able to tell you. But that being said, I think the whole line of investigation to induce thymic rejuvenation, I think is an important one area, especially if we're thinking about increasing lifespan further for what we are doing now. That in the future, it will become one of these rate limiting step. It's a bit the same situation as the ovary, where the ovary and the endothermis, we call them the canary in the coal mine. I mean, there really are specific organs that show, et cetera, aging way earlier than other tissues. Now, the question is, why is the thymic involuting so early? I think it's probably because evolutionary we were never meant to live this old.

• 57:35Speaker 01

  And so that really is one of the thinking that goes on. That's going to be, in the long term, one of the problems that we have to face. And this is something we're actively studying and the lab is trying to, we just completed a study where we are looking for novel biomarkers that are predictive of whether you will respond to a vaccination or not. And it's something done in collaboration, Mark Davis at Stanford, using the 1000 Immunome Project, which is one of the largest studies studying aging in the immune system, only in humans. So we've been able to, studying people to identify some metabolites that are associated with poor response to vaccine. And so those are not only markers, but they could also become tools that we include in as adjuvant or as a pre-treatmentary.

• 58:20Speaker 01

  I'm sure you're familiar with the work of Joan Manick.

• 58:22Dr. Peter Attia?

  Of course. Yeah, I was going to ask you about Manick and Kluivstein in a moment. Before we do, I want to go back to this point here, which is biomarkers are so important. When I think about cardiovascular disease, and even though it's the leading cause of death, why I tell my patients, it's the one you need to be least afraid of if you're willing to be proactive in management. And it comes down to the fact that we just have Such a clear understanding of how the disease works and we have exceptional biomarkers. So we can measure the things that are causing the disease. We can measure inflammation, we can measure ApoB, we can measure VLDL cholesterol, LP little a. We can measure blood pressure, we can measure metabolic health and we know how to address those things.

• 59:07Dr. Peter Attia?

  And we know that when we address those things, we can measure whether what we're doing is working. Okay, so problem solved, basically. When it comes to the immune system, we're going to talk about Manic and Clixtein in a moment. But as we saw from their paper 10 years ago, they gave a rapamycin analog to people. People who were in their 60s vaccinated them and demonstrated that, oh, boy, you got a much better immune response. Okay, they were able to demonstrate that using laboratory techniques. I'm sure they used flow cytometry or something like that to measure it. How close are we to being able to do that sort of thing commercially? By commercially, I mean over the counter.

• 59:48Speaker 01

  Not close. I think in that study, they actually measured antibody titers.

• 59:53Dr. Peter Attia?

  So even more complicated than flow cytometry?

• 59:55Speaker 01

  Yes.

• 59:56Dr. Peter Attia?

  Okay.

• 59:56Speaker 01

  In that case, they definitely showed an enhancing effect with a known Jero protector. This was a-

• 1:00:02Dr. Peter Attia?

  A suspected Jero protector, at least in humans.

• 1:00:04Speaker 01

  Exactly, a rapalog. And they showed not only increased titers, but also protection, increased protection. Eventually, the clinical trial failed for a whole series of other reasons, which were in part due to the way that the FDA imposed the trial to be generated. I think it just complicated the whole picture.

• 1:00:23Dr. Peter Attia?

  Yeah, by the way, for folks listening to us who are confused by that, Matt Kabelin and I had a specific discussion because it wasn't the 2014 trial. It was a later trial. It wasn't the RAD 001 trial. It was the other trial that failed. And I actually don't remember the reason. But Matt explained that it was very clear that it was a tragedy of bureaucracy.

• 1:00:47Speaker 01

  It is.

• 1:00:47Dr. Peter Attia?

  And it shouldn't be viewed as a black eye on that molecule.

• 1:00:51Speaker 01

  Yeah, Matt is more of a specialist in the whole rapamycin. So I will defer to what he said.

• 1:00:55Dr. Peter Attia?

  We'll link in the show notes to where Matt and I had that discussion.

• 1:00:58Speaker 01

  Yeah, what I've heard from anyone that I've talked to, including Joan, is that this was in some way bungled, which is sad because sometimes things like this can put a field back for a number of years, discourage investors. We have a startup that originated at the back called Eovian, which has raised $50 million, again, coming up with rapalogs, novel rapalogs, that are going to be, I think, revisiting that whole picture. So we're quite excited. The field is far from being dead.

• 1:01:25Dr. Peter Attia?

  Will we ever be able to measure this in people the way we measure hemoglobin A1C or things like that? Or is it going to be one of those things where it's a bit of a leap of faith? And you're going to have to look at the clinical trial where the outcome was there. And then you're just going to have to say, well, even though there was probably massive heterogeneity amongst the participants in the trial, we're going to dose this thing individually. I mean, it's a little bit like, you brought up vitamin D earlier. I mean, one of the problems with the vitamin D trials is that they're all garbage because they all just give people a given dose. They don't measure the response. They don't measure compliance. A vitamin D trial should be done based on target level, not target dose. And we run the risk here of the same thing in a much more complicated system.

• 1:02:10Speaker 01

  Agree. That being said, measuring pathogen-specific titers is done routinely in the clinic. I don't know if you did this, but I just had my measles titer measured. I was born in 1957, which is right the age. Before 1957, everyone was exposed to measles. So you're typically safe, but you should measure your titer to determine whether you need to be revaccinated. I found out that, yeah, you can do this very easily. You get a titer.

• 1:02:40Dr. Peter Attia?

  Would the titers by themselves tell you? So what would you predict? If I measured every titer right now?

• 1:02:47Speaker 01

  Yes.

• 1:02:47Dr. Peter Attia?

  If I measured polio, shingles, did a pan titer on you? And then started you on rapamycin for eight weeks and then stopped it and then remeasured your titers without vaccinating you, what would you expect to see?

• 1:03:02Speaker 01

  I would not expect them to change.

• 1:03:03Dr. Peter Attia?

  Yeah, exactly. So how do we know we're improving your immune system if indeed we have?

• 1:03:08Speaker 01

  Oh, I see what you're saying. So in terms of if we were to start you on rapamycin, what would happen?

• 1:03:13Dr. Peter Attia?

  Yes. How could we measure the improvement in immune function?

• 1:03:16Speaker 01

  By the way, the MANIC trial showed that first they did a one-month treatment with the rapaloc before vaccination. They demonstrated not an effect on existing vaccinations, but it only demonstrated on de novo vaccination.

• 1:03:31Dr. Peter Attia?

  That's right.

• 1:03:32Speaker 01

  And I think what would be the effect on existing titers against all of the other pathogens? I don't know. I don't think this has ever been done.

• 1:03:40Dr. Peter Attia?

  Yeah, interesting. You want to just say a little bit more about that trial? So that was, at least for me, a pivotal moment in my journey in this space and in understanding this world. So that was December of 2014 that paper came out and if I recall, roughly 300 plus participants divided into four groups. So placebo group, a group that got one milligram every day, a group that got five milligrams once a week, and a group that got 20 milligrams once a week. Two people were pulsed, one much higher than the other, and then one given daily and then a placebo. I believe they were all over 65. I think the study was done in Australia. And as you said, they were put on their whatever treatment was for four weeks, immunized, I think it was another four weeks, and then a six-week

• 1:04:22Dr. Peter Attia?

  washout, and then the titers were checked. The best response, I think, was in the five milligram pulse and the 20-milligram pulse. The one-milligram daily still had a better response than the placebo, but not as strong as the two pulse doses. But the five and the 20 weekly were nearly identical, but the 20 had much more side effects. I don't remember perfectly, so correct me if I'm wrong.

• 1:04:45Speaker 01

  You'll remember pretty well.

• 1:04:46Dr. Peter Attia?

  The takeaway was basically five-milligram pulse was the sweet spot. You get all the benefit without the side effects.

• 1:04:52Speaker 01

  That's how I remember that trial as well, although I'm always impressed by how you remember all of the details of these clinical trials. What was remarkable about that data was the fact that this is from a drug that

• 1:05:05Dr. Peter Attia?

  It's supposed to be an immunosuppressant.

• 1:05:06Speaker 01

  An immunosuppressant. And it's been a long road for the longevity field to try to get our colleagues who are actually using rapamycin as an immunosuppressant to have them believe that this actually has an effect on immunity. And not only not immunosuppressive, but actually a promoting immunity.

• 1:05:24Dr. Peter Attia?

  How do you reconcile that? Not their disbelief, which is warranted, but how do you reconcile that one molecule? So if you think about the doses we used to give rapamycin, it's not actually used that much, by the way, today in the transplant clinic. So FK506, I'm blanking on what FK506's real name is, but anyway, whatever, it's largely displaced serolimus, which is Rappa. But that said, when we used to give it out, we were giving two to four milligrams a day. Now, let's just assume that it was indeed contributing to prevention of organ rejection. Do you think it was doing so because that's a high enough dose of constitutively giving a drug that it suppresses the immune system? Or do you think it was only suppressing the immune system because it was being given

• 1:06:07Dr. Peter Attia?

  in combination with two other drugs? And it was only as part of that sea of other drugs that it has the immunosuppressive effects?

• 1:06:16Speaker 01

  I think there's clear evidence it is immunosuppressive by itself. I can tell you that for the period when I was on rapamycin, I would take either four or six milligrams a week, every morning, once a week. The biggest difference between the immunosuppressive and the geroprotective effect is really the amount, the frequency and the amount. The reason why people adopted this once weekly dose is to first, not have an immunosuppression, and second, to mitigate the secondary effect, which are thought to be caused by inhibition of mTOR2, which is the second complex.

• 1:06:51Dr. Peter Attia?

  Right, this is the glucose issue.

• 1:06:52Speaker 01

  The glucose effect. And that seems to be working largely. What was, in my case, remarkable is that every time I took my dose, not two, I only did two. For a couple of weeks, but either four, six. The next morning I would have a pimple on my nose. So I was immunosuppressed, clearly, every single time.

• 1:07:10Dr. Peter Attia?

  For a day.

• 1:07:10Speaker 01

  Yeah, for a day, for a day or two. I sort of made peace with it in the fact that if I had a really heavy workout, I would have exactly the same thing. Exercise is immunosuppressive. If you go all out, you can get a cold. You're temporarily fragilized after a really heavy exercise. So I think the difference really between these two worlds, the immunosuppression, which clearly has been documented by clinical trials, it is immunosuppressive by itself, versus the beneficial effect on the immune system, to me is a question of dosage and frequency.

• 1:07:41Dr. Peter Attia?

  And yet, I cannot reconcile the unambiguous success of the interventions testing program, where those mice were eating rapamycin in every single bite of food they took. In fact, they were consuming it more continuously than even the most immune-compromised patient. And without exception, every single ITP study of rapamycin, whether they started in old mice or young mice, rapa alone, rapa with another drug, it just doesn't matter. It always worked. How do we reconcile that?

• 1:08:18Speaker 01

  Well, I don't have the answer, but I can sort of talk about it. There's something that worries me about our reliance on the mouse as a model system for aging, for studying aging, and how relevant it is to us as species.

• 1:08:33Dr. Peter Attia?

  Even mice, because we would all admit that the ITP mice are the best, they're the Ferrari of mice.

• 1:08:38Speaker 01

  Exactly. The ITP is the best, is the best way to address this question because they're using mice that are crossed.

• 1:08:46Dr. Peter Attia?

  Yep.

• 1:08:46Speaker 01

  So it's not.

• 1:08:46Dr. Peter Attia?

  Not inbred, yep.

• 1:08:47Speaker 01

  Not inbred. When you're using black six, you're essentially doing the experiment on N of one. And the whole world, I mean, eighty percent of the work that's being done in mice is done on black six. We're all studying the same person. So obviously, when you go and try to transfer this to a human population with all of its variation. So the ITP did the right thing. That being said, and this is not an attack on ITP. I think ITP is a great program. And should be funded and should continue to study this. I just worry about the over reliance on ITP alone. And I think we should have another system that studies primate interventions with drugs. There are a number of primates, non-human primates that are actually much closer to us.

• 1:09:30Speaker 01

  The reason I worry about mouse is something that actually Steve Arstad, you've had on this podcast as well. Steve is a good friend and he came up with something called the longevity quotient, which I think is something that people do not pay attention enough. So the longevity quotient is this idea that if you look across the animal kingdom, the larger you are, the longer you live. Okay, so you can take thousand species and you can, on the X axis, you have their size. On a Y axis, their life expectancy.

• 1:09:59Dr. Peter Attia?

  It largely rises to the right.

• 1:10:01Speaker 01

  And you can see a monotonous curve. Now, there are exceptions to this. One of them is naked mole rats, for example.

• 1:10:10Dr. Peter Attia?

  They punch above their weight. Dogs tend to punch below their weight.

• 1:10:12Speaker 01

  Exactly. Although in dogs, again.

• 1:10:14Dr. Peter Attia?

  Varies by, within the size thing, it seems to hold.

• 1:10:16Speaker 01

  This is between species, then when you look intra-species, it gets even more complicated, which is the larger dog live shorter than the smaller dogs. The Great Dane versus the Chihuahua, and that is down, actually that's driven mostly by growth hormone, which is again, another reason why we should look at taking growth hormone as an anti-aging drug with some degree of circumspection, because in dogs, the more growth hormone you have, the larger you are and the shorter you live. We know also in humans, the larger you are, the taller you are, the shorter you live. So are these effective growth hormone? Yes. Are they only important while during the growth phase? That's a possibility, but it's something that really gives me pause to go back to our discussion about growth hormone.

• 1:11:00Speaker 01

  So going back to the longevity quotient, mice are also an exception. They punch below their weight, so they live shorter than they should based on their size. And humans is the biggest exception. We live about five to six times longer than we should based on our size, which tells me that we are the naked mole rats of primates. We do incredibly well, which means that we already have optimized a lot of these pathways that are promoting aging. I suspect the mice is exactly the opposite. I don't know that someone has really compared sort of intrinsic tor activity in mice. Are they, for example, living? Mice are, especially laboratory mice, are engineered to reproduce and grow as quickly

• 1:11:43Speaker 01

  as possible. They have large litter size. They do everything very quickly. Now, we know all of these activities are requiring a lot of anabolic strength, which is driven by tor. So the question is, are the mice examples of animals that are maximizing tor activity to do everything they do very quickly? And we are maybe at the other end of the spectrum where we have low basal tor activity. So that's where I worry when people just transfer everything we know from tor, from mice into humans and saying it's going to show and work in humans. I don't know if you

• 1:12:18Dr. Peter Attia?

  Such an interesting point.

• 1:12:19Speaker 01

  Yeah. And this is frankly, why I stopped taking rapamycin. I thought I did not really see anything in terms of anything metabolically, physically, muscle strength. I could not, in contrast to GLP-1 agonists, where I saw all of my numbers get better and functionally strength, all of this. I saw everything getting better on GLP-1 agonists. With rapamycin, I never could tell whether I was taking it or not.

• 1:12:43Dr. Peter Attia?

  Yeah, although it's not just that. I would say where rapamycin acts, I don't know that we would see anything getting significantly better. Because if we think that the main places that rapamycin is going to act would be on autophagy, well, there's no way you're going to measure autophagy. You're not going to feel autophagy. You're not going to see it or measure it. Does it tamp down on certain subsets of senescent cells? That's certainly plausible. Again, I don't know how we're going to see or measure or necessarily even feel that. Does it reduce some of the tonic, low-grade, unhelpful inflammation? Probably. But again, if a person doesn't have much to begin with, it's going to be tough to

• 1:13:25Dr. Peter Attia?

  measure. Conversely, GLP-1 agonists act directly on a thing that is so easy.

• 1:13:32Dr. Peter Attia?

  Easy to measure, which is glucose metabolism and body weight for those who are losing weight as well. So it might not be a fair comparison. I guess the other thing I would add to this interesting observation is that, of course, the mice in the ITP are still in a relatively sterile environment. And it might be that even if they incur some immunosuppression, it's not going to be as maladaptive as it would be if they were wild animals as we are.

• 1:13:56Speaker 01

  They live in a sterile environment. They live grouped in a cage with no ability to move, to exercise. They eat a diet which makes the American diet look like the most healthy thing ever. I mean, have you ever seen the pellets that these mice are eating?

• 1:14:15Dr. Peter Attia?

  Do the ITP mice eat the crappy pellets as well?

• 1:14:18Speaker 01

  I suspect they're eating.

• 1:14:19Dr. Peter Attia?

  Okay, I don't actually know what their diet is.

• 1:14:21Speaker 01

  Yeah, I don't know what their diet is. I can guarantee you they're not eating salad and fruits and vegetables. So in some way, they are an incredibly artificially bad sort of environment. These mice are actually doing everything that is conducive to a poor health. And so the fact that we see something that works in that system might have some value for a fraction of the population that has a very poor lifestyle. I do worry about transferring this to someone like you and I, who are exercising or trying to eat well, trying to sleep and all of this. I take these observations with some degree of caution. And frankly, when people ask me, should I go on rapamycin? I do worry. Now, this is a different story.

• 1:15:03Speaker 01

  If someone, a patient comes and sees you at 40 years old and tells you, I think I want to go on rapamycin. I would strongly argue that you should not do this. Because even in the studies that have been conducted, they still side effect in mice that were the equivalent of 65 to 70 years old. Now, if you're 75 years old and you have the feeling you're chronically inflamed and you have the feeling that things are not doing well, there are a number of anecdotal cases where people have described really feeling a lot better and a lot stronger very quickly.

• 1:15:31Dr. Peter Attia?

  On rapamycin?

• 1:15:32Speaker 01

  On rapamycin, but I would predict it would be the same thing with a growth hormone or some of these interventions. So I really put those in different categories. My argument to people is today we have one intervention that is very profoundly anti-aging and it is physical activity, exercise in all of its forms. Once you have optimized this, I think let's talk about doing something else on top of that.

• 1:15:55Dr. Peter Attia?

  Earlier you brought up the sirtuin story and NAD. I'd love to spend a little bit of time there. I was at a talk recently and as always, I get asked questions about stuff like that. And I got asked the question about NAD. And I said, look, this is one of those things where if I tell you the following facts, I'm going to tell you three facts. NAD is completely ubiquitous throughout the body and it is absolutely essential for the most important chemical reactions that happen in the body. You cannot undergo redox reactions, metabolic reactions without NAD. That is point one.

• 1:16:33Dr. Peter Attia?

  Point two is a class of proteins called sirtuins rely heavily on NAD as the substrate in the process of repairing DNA. That is fact two. Fact three is as you age, NAD levels decline precipitously. Okay, those are three facts and I don't believe, is there any dispute to any of those facts?

• 1:16:56Speaker 01

  No controversy.

• 1:16:57Dr. Peter Attia?

  Okay. Armed with those three facts, how could it be that supplementing NAD does not lead to a longer, better life or some health benefit? That's a logical conclusion, right?

• 1:17:11Speaker 01

  Well, not completely because it depends also what is the reason why NAD levels decrease and it depends also what supplements are you remedying.

• 1:17:21Dr. Peter Attia?

  Yes, yes, yes.

• 1:17:22Speaker 01

  And this is something I love to talk about CD38.

• 1:17:25Dr. Peter Attia?

  So it could be that NAD levels go down because their consumption goes up. As we age, there's more DNA damage, there's more consumption, the sirtuins need more of it and it goes up. And then of course, the question would become, is the current level of NAD that we have rate limiting to that reaction? If not, then all the extra NAD in the world should have no benefit because you're just adding more substrate to a reaction where it's not needed. Conversely, if NAD levels are going down because there's a production issue and if you provided more of it, you could actually do more good, well then it could be the exact opposite story. So let me pause there for a moment and have you fill in the edges of everything I just said so that we can go deeper into this discussion. So maybe explain a little bit what NAD is, explain what it means in redox and obviously

• 1:18:10Dr. Peter Attia?

  let's talk about sirtuins and the role that NAD plays there.

• 1:18:13Speaker 01

  Lots to unpack there. It could be a two hour podcast. It's one area that we've worked on for the last 25 years. We were responsible for cloning the human sirtuins, actually. After Lenny Garante published his paper on sirtu in yeast, we were the graduate student.

• 1:18:29Dr. Peter Attia?

  Matt was the first to publish this, wasn't he? Kabelin.

• 1:18:31Speaker 01

  Yeah, actually Matt and Brian, I mean, David, I mean, that whole gang was the original gang, along with Lenny Garante, were paved the way for a lot of what we know. One thing that I would just start by saying is that it pains me in some way in a field that is so rich and has generated so much data that there's a whole cloud lying on top of sirtuins and NAD. There's nothing there. I just tell people, it is an incredibly studied system. We are still juggling the complexity. And I would argue that any field where the same degree of investigation will be conducted will have the same controversy. This is the nature of science. The beauty of science is that it's incredibly messy on the way up,

• 1:19:15Speaker 01

  but eventually things are getting clarified. And I think in the terms of the sirtuins, we're still right in the middle of it. So there's some complete garbage.

• 1:19:23Dr. Peter Attia?

  Yeah. And by the way, I'm not completely dismissive. What I will say has made, has made this field complicated is that the leading proponents of it have all opted for a commercial pathway. And therefore they have opted not to study this in a rigorous way, but to study it in a commercial way. And I mean, I understand why you would do that. Like, that's the nature of it. And this is not a molecule that you're not going to generate intellectual property in the same way that you would around a novel drug. And so it poses a limitation to how these things can be studied. But unfortunately, that coupled with the risveratrol fiasco, unless you think otherwise, Eric, we don't need to talk about risveratrol. I remain completely convinced that risveratrol had zero benefit whatsoever.

• 1:20:07Dr. Peter Attia?

  I think it is an absolutely useless molecule. So I think that risveratrol debacle, the overhype, complete debacle of that, coupled with the fact that all of the participants in the NAD landscape are doing it through their own commercial enterprise with their own proprietary. Blended has resulted in this inability to drive forward in this field.

• 1:20:28Speaker 01

  I agree. You've identified the problems, the hype and the commercialization. I mean, commercialization can be helpful if the companies are actually willing to invest in clinical trials and so on. I always use the example of Timeline, Urolithin A. I mean, we've worked with them. They do clinical trials, rigorous. They publish them in the best journals and at the end you know what you're measuring. That being said for the sirtuins, so let's try to be step back and given the controversy, I would say I would encourage your listener not to just discard it all. We're still in the middle of it and I think there's something interesting will emerge out of it. So NAD is a critical intermediary metabolite.

• 1:21:07Speaker 01

  It has two big roles. First is it plays a key role in Redux reactions. Again, we've talked about these reaction reduction oxidation.

• 1:21:15Dr. Peter Attia?

  Anytime electrons need to move around.

• 1:21:16Speaker 01

  Exactly. So it exists in two forms, NAD and ADH, and it's critical to intermediary metabolism. There are more than 600 of these enzymes that use NAD in the whole metabolism. So it stands to reason that if you're losing NAD levels, you go below a certain critical level, these enzymes are going to suffer. Your whole metabolism is going to go down and we know by the way that decreasing metabolic efficiency at all level is one of the hallmarks of aging. So in addition to these enzymes that utilize the NAD, NADH couple, there's a whole series of other enzyme that actually are digesting, cleaving NAD.

• 1:21:55Speaker 01

  And these would be the PARPs, polyhdipoyurebose polymerase. So these are enzymes mostly involved in DNA repair. So it plays a critical role. The sirtuins, seven sirtuins, all doing different things within the cell. And we can go back and dig into this a little bit in terms of what are the sirtuins doing. There's also another two enzymes called CD38 and CD157. These are also NAD hydrolyses and we are studying them a lot. So that's, I guess, the background of what these enzymes are doing. One thing that your listeners should know about NAD levels and why the decrease in NAD levels are relevant to aging with respect to the sirtuins. Because sirtuins have a relatively

• 1:22:40Speaker 01

  Narrow range of KD for NAD. So if the NAD levels change, as we know they do during aging, it will lead to a change in the activity of the sirtuins. And I think this is something that was proposed by Lenny Garante back in the days, showed, for example, even during fasting, your NAD levels will increase and this will activate sirtuin. So I think this is something that's really unique to the sirtuin. And we know this in a really acute way because there are sirtuins that are present in the cytoplasm versus in mitochondria versus in the nucleus. And the NAD levels in each of these organs are very different. For example, much higher

• 1:23:20Speaker 01

  in mitochondria. It turns out that 33 has a KD for NAD, which is much higher than 31. And so variations, or that really is the indication that they are sensors of NAD levels, which goes back to the initial model that you mentioned, NAD levels change during aging, therefore, we can expect the activity of the sirtuins to change. Now, what else have I not addressed in your initial batch of questions?

• 1:23:49Dr. Peter Attia?

  I think we're now ready to then move on to, if we believe with some conviction that restoring NAD levels in an aging individual is beneficial, we now have to deal with the same problem you deal with any small molecule, or large molecule for that matter. How do you get it in the body? So what are the ways in which you could get NAD into the body, directly or indirectly?

• 1:24:16Speaker 01

  So that brings me to maybe another element of the biochemistry. So one thing that has emerged is this idea that the question is to why do NAD level decrease? And there's been lots of theories. Activation of the PARPs, that seems to be happening in C. elegans. In mammals, this is the work of Eduardo Cini, was the first one to show that CD38 appears to be the major driver of the decrease of NAD during aging. And the way that he's demonstrated this, and we've actually repeated some of his results and published on this as well. If you study a mouse that's knocked out for CD38, you find that NAD levels actually do not decrease during aging. And that's pretty much across all organs.

• 1:25:00Speaker 01

  And I think what this does is really brings the whole question in terms of what should we be targeting?

• 1:25:06Dr. Peter Attia?

  Did we talk about what CD38 is doing specifically?

• 1:25:08Speaker 01

  Yeah, so CD38 is a membrane anchored protein. Some of it is facing outward on the outside of the cell. Some of it is facing inward. For example, in T cells, it's mostly facing outward. In macrophage, it's mostly facing inward. And it is an NAD hydrolyse. Now, what is it doing in the immune system? Why do we have it? Not entirely clear. One idea is that because it is present in T cells-

• 1:25:34Dr. Peter Attia?

  Is it on non-immune cells?

• 1:25:37Speaker 01

  And the T cells as well. One idea, at least for the immune system, is that it might come up and eat up all the NAD that's local in the extracellular fluid, although there's not much of it, and limit the abilities as part of the innate immune response and limit the ability of bacteria and other organisms to actually access these micronutrients for their own growth. That's one thinking. But I think it's a lot more complicated than this. And we're really in the middle of it. I have a good part of my lab actually studying the role of CD38 in the immune system and in endothelial cells and in the brain as well.

• 1:26:12Dr. Peter Attia?

  Now, you mentioned a moment ago that the CD38 knockouts do not see a decline in NAD with aging.

• 1:26:18Speaker 01

  Zero, and they live longer.

• 1:26:19Dr. Peter Attia?

  I was just about to say, what is the phenotype of a CD38 knockout? What deficiency do they have?

• 1:26:24Speaker 01

  Nothing that we can tell, and they live longer.

• 1:26:26Dr. Peter Attia?

  How much longer?

• 1:26:27Speaker 01

  15%.

• 1:26:29Dr. Peter Attia?

  That's comparable to rapamycin.

• 1:26:30Speaker 01

  Yeah, it's pretty significant. This has been published by Eduardo Chinney.

• 1:26:34Dr. Peter Attia?

  Do you think that that is true, true and unrelated to the increased pool of NAD?

• 1:26:40Speaker 01

  Now, CD38, that's a key question, and that's one that's not been answered. And I would say, if I had to go on a limb, I would say it's not linked to the NAD decrease.

• 1:26:51Dr. Peter Attia?

  Just to make sure everybody understands what you're saying. Your belief is that the CD38 mouse, the knockout, does not live longer because he has more NAD. That's just another issue we're seeing and that there's something else about that mouse.

• 1:27:03Speaker 01

  Yes, or it might be partially the NAD and partially the other mechanism I'm about to discuss. One thing that's remarkable is that as we age, us and mice, we see an increase in CD38 level across the organism, especially in the immune system. We've published a paper showing that the SARS from senescent cells is a very powerful inducer of CD38 expression in macrophages. So that's one mechanism by which we're linking senescence and the SARS to increase CD38, leading to a depletion of NAD and other effect.

• 1:27:37Dr. Peter Attia?

  And yet we have no idea what it's doing, other than hydrolyzing NAD.

• 1:27:40Speaker 01

  It has a cognate receptor on other cells. They don't seem to be immune deficient. It's really one of these players that people, there are hundreds of papers.

• 1:27:49Dr. Peter Attia?

  Do you think it plays a role in inflammation? A negative role in inflammation?

• 1:27:52Speaker 01

  One idea about it is that it plays a suppressive role in the immune response because we see it being induced latish in the immune response and the idea it comes on to tampon down.

• 1:28:04Dr. Peter Attia?

  So it's actually the exact opposite. It's so pro anti-inflammatory that it can be harmful in that way, as opposed to contributing to sterile inflammation, which is the more typical problem we see in aging.

• 1:28:16Speaker 01

  Yeah, we did not discuss this. The other side of the immune system is that it has to be incredibly balanced between reacting appropriately towards exogenous pathogen, but not reacting against the self. As you know, as a physician, there are so many conditions that are a manifestation of an excess of immune response against the individual. All of the autoimmune diseases, which by the way, increase during aging, so.

• 1:28:43Dr. Peter Attia?

  Except for type 1 diabetes.

• 1:28:44Speaker 01

  Yes, that's the one young.

• 1:28:46Dr. Peter Attia?

  I know that you used to study that. Why do you think that is?

• 1:28:49Speaker 01

  It's really an interesting question, although there's something called LADA that I'm sure you've heard about that is emerging, that we might have been diagnosing some type 2 that were actually late type 1. The thing that is really unique about type 1 is the fact that I remember a number of papers that highlight the fact that there might be something happening during development that exposes the immune system to the developing beta cells and that might trigger more autoimmunity at that time. It could also be linked to the fact that there's been for many years a discussion of the role of viruses, infection and molecular mimicry between some of these viruses and beta cells.

• 1:29:31Speaker 01

  So it could be that a subset of infections that happen during childhood actually puts you at risk of activating your immune system inappropriately. That's the whole idea, but there's clearly an increase of autoimmunity throughout life.

• 1:29:45Dr. Peter Attia?

  By the way, CD157, do we see the same effects? Do we have a CD157 knockout?

• 1:29:50Speaker 01

  No, much less studied. There is some interesting effect also, but CD38 has garnered most of the attention. If you think about, I'll go back about CD38 in terms of what it's doing. It's taking NAD and cleaving it into ADP ribose, which is sugar and nucleotide and nicotinamide. Nicotinamide is a precursor to NAD. And so this nicotinamide, which is generated by CD38, but by the sirtuins, by the PARPs, normally gets recycled in a two-step reaction all the way back to NAD. Now, what's really interesting is if you block this, it's called the salvage pathway for nicotinamide, if you block it, within a few hours, your NAD levels go down to zero.

• 1:30:35Speaker 01

  So the system-

• 1:30:36Dr. Peter Attia?

  Wow, heavily dependent on recycling.

• 1:30:38Speaker 01

  Incredible, actually. And there's a specific inhibitor of this enzyme called NEMPT. You can add it to cells. We've done the experiment. Within four to six hours, NAD levels down to zero, the cell dies. So there's an incredible churning through that whole pathway, which is a reflection of the activity of sirtuins, CD38, CD157, the PARPs and so on. So you have a situation during aging where CD38 increases. You increase the degradation, so you decrease the pool of NAD.

• 1:31:09Dr. Peter Attia?

  But you're increasing, in theory, the metabolites.

• 1:31:12Speaker 01

  You're increasing the metabolite, nicotinamide. Now, one important thing is nicotinamide metabolism is either salvaged back to NAD or methylation by an enzyme. And this is important for supplementation because it turns out CD38 not only cleaves NAD, but it also cleaves NMN, which is one of the two precursors, NMN and NR. So when you actually have increased CD38 activity and you take NMN, you churn through this pathway and actually you increase your nicotinamide and you increase its methylation.

• 1:31:45Dr. Peter Attia?

  So NMN is also cleaved by CD38?

• 1:31:47Speaker 01

  Yes.

• 1:31:47Dr. Peter Attia?

  Into what?

• 1:31:48Speaker 01

  Into...

• 1:31:49Dr. Peter Attia?

  Nicotinamide plus something that's not ADP ribose?

• 1:31:51Speaker 01

  Yes, yes.

• 1:31:52Dr. Peter Attia?

  Okay.

• 1:31:53Speaker 01

  And so when you do this, you're increasing your level of nicotinamide to the point that it's shunting to methyl nicotinamide, starts depleting your one-carbon cycle. So what you see in a number of people, actually on NMN, is their homocysteine level going up, including me. I stopped taking it when I saw this. I thought this is not... I was taking about a gram of NMN for a while, and then I saw my homocysteine level going up, I think as a reflection of this pathway, and basically stopped it.

• 1:32:24Dr. Peter Attia?

  Now, why is it, Eric, that the increased pool of nicotinamide preferentially goes down a methylation pathway as opposed to the salvage pathway to give you more NAD?

• 1:32:34Speaker 01

  Yeah, I don't think it goes preferentially. It just depends how much...

• 1:32:37Dr. Peter Attia?

  It's just the more you put in, even if it splits stocheometrically or stochastically even, you're going to take away one carbon.

• 1:32:45Speaker 01

  Yeah, and I do not know what the relative proportion is, but clearly, the more you drive the system with NMN, the more you're going to yield these...

• 1:32:54Dr. Peter Attia?

  How much did your homocysteine go up, by the way?

• 1:32:56Speaker 01

  Up to 15.

• 1:32:57Dr. Peter Attia?

  From?

• 1:32:58Speaker 01

  From typical seven.

• 1:33:01Dr. Peter Attia?

  Wow, that's a big jump. And then how long did it take to resolve once you stopped the NMN?

• 1:33:06Speaker 01

  I measured typically every three months. After three to six months, it had gone back to normal, seven to eight.

• 1:33:12Dr. Peter Attia?

  What about NR, nicotinamide riboside? How is that treated by CD38?

• 1:33:16Speaker 01

  It's not metabolized by itself. NR eventually in the cell has to make it back to NMN, which is on the salvage pathway that we talked about. So NR is less bulky, less big than NMN. So it is able to get into the cell, but eventually it makes it into nicotinamide NMN and then goes back into the same pathway. So eventually they all come back to the same.

• 1:33:40Dr. Peter Attia?

  So do you think that there's no difference between the same amount of NR and NMN?

• 1:33:44Speaker 01

  No, there clearly are some differences, especially in all the really complex biochemistry that happens in terms of getting them into cells. The problem with NR and NMN is that if you think about what the approach is, you essentially you have a pool of NAD, which is a sink. Think about a sink full of water. It's leaking. That's your CD38. That's the leak at the bottom of the sink. And you keep pouring more NMN, more NR inside of it. It's just going to accelerate the leak. You're not going to solve the problem, basically. Maybe you'll reestablish the level at a normal, semi-normal, but the churning through is problematic. Now, why is the churning through problematic? Because some of the byproducts of CD38,

• 1:34:27Speaker 01

  for example, are cyclic ADP ribos. So there's two forms of ADP ribos, not cyclased and cyclized. The cyclized activates calcium signaling. And so there's a whole aspect of the biology of CD38 that's linked to calcium signaling. So I think I do worry about the supplementation with the NR and NMN. I do worry about it. I'm not discounting them. I think clinical trials are ongoing. There's dozens of clinical trials. So we will soon identify something in which it has a benefit. Again, if you think about the metabolism of these metabolites, it's incredibly complicated. There are effects on the microbiome.

• 1:35:10Speaker 01

  Their effects on different absorption by different cells. Just literature, hundreds and hundreds of papers, I think way beyond what your audience party wants to hear. But I would say at this point, most of what you can buy a supplement have doses that are so low. This is where there's an important discordance also. When we do experiment, we've seen amazing things in laboratory animals in terms of supplementing with an RNNMN. This is where the excitement comes from. But typically, these animals are getting 10 times more than what you're buying as a supplement. And the reason is, I think, GRAS status is given to these companies to give a small amount.

• 1:35:50Dr. Peter Attia?

  GRAS, meaning generally regarded as safe, the FDA's criteria for giving something that is naturally occurring.

• 1:35:56Speaker 01

  Yes.

• 1:35:56Dr. Peter Attia?

  Yeah, but doesn't require it to go down the IND pharmacologic pathway. Eric, if you were taking one gram a day of NMN and your homocysteine went from seven to 15, I guess two questions would be, has that been reported elsewhere? Is that a known phenomenon? In the trials that are testing NMN, are they measuring homocysteine to see if that's?

• 1:36:15Speaker 01

  I, I must have read it somewhere because I was, I was.

• 1:36:19Dr. Peter Attia?

  You were looking for it.

• 1:36:19Speaker 01

  I was looking for it, yes.

• 1:36:20Dr. Peter Attia?

  And then the second question is, how would you then tolerate 10 grams of NMN? I mean, if one gram is doing that, you would deplete all one carbon. Does that mean you wouldn't even be able to alter your epigenome in ways that might be favorable?

• 1:36:34Speaker 01

  You run all kinds of risk and a number of people that I've seen the same thing and start taking trimethoglycine to try to supplement this, I do worry about this. I think for me, I want to reiterate the fact that I think the data and animal models of some of the things that we've seen with some of these precursors is really interesting. And this is why there's so much interest.

• 1:36:53Dr. Peter Attia?

  Did you ever try using TMG to see if it would offset the?

• 1:36:56Speaker 01

  No, I didn't.

• 1:36:57Dr. Peter Attia?

  Okay, that would be an interesting little self experiment. Okay, what about intravenous NAD?

• 1:37:03Speaker 01

  So that is one of my pet peeves. I try in everything to remain open minded to things I don't know and don't understand. My prediction is that first NAD is not a an extracellular molecule. NAD does not exist, almost does not exist at all in the plasma. It is an intracellular. As I mentioned, high concentration in mitochondria, much lower in the cytoplasm and in nucleus. So the whole idea of injecting intravenous NADs, first, it's too big to be absorbed by cells. So what is the body doing with it? There is a famous paper by Joshua Robinowitz that showed that if you inject it actually intravenously,

• 1:37:47Speaker 01

  you actually get it mostly catalyzed by the liver into nicotinamide. Nicotinamide is one of the fraction of niacin. You can buy this at the pharmacy for very cheap. You can go into an IV clinic and get a $700 injection of NAD. Very few studies, one or two. I've read both of them. They're interesting. My opinion is that NAD intravenously is not something that should be done. The same thing for subcutaneously. I've seen another company that sells it subcutaneously. Really no evidence for doing this. Now that being said, I've heard, and this is where I try to remain open minded. Obviously, we don't know everything.

• 1:38:30Speaker 01

  I have heard anecdotal evidence of dramatic effect in some patients with Parkinson's. People really describing, not a miraculous, but near miraculous effect, right after the infusion, having increase in motor performance that you can really assess in someone who's as severe Parkinson's. So not studied systematically.

• 1:38:51Dr. Peter Attia?

  Mechanistically, is there a reason you could explain that?

• 1:38:54Speaker 01

  Yes.

• 1:38:55Dr. Peter Attia?

  Through dopamine or something else?

• 1:38:56Speaker 01

  There's a whole literature on the effect of NAD precursors and so on, on Parkinson's, mostly animal models. And I think there are lots of clinical trials going on in Parkinson's as well, but more using the standard NR and NMN. The thing that I've described is more a couple of friends who've told me I've seen this. Not enough to make a product, but enough maybe to question, maybe there's something more to it than what we truly know. But the proliferation of these intravenous clinic, frankly...

• 1:39:25Dr. Peter Attia?

  How complicated is it to produce a bag of intravenous NAD?

• 1:39:29Speaker 01

  I don't think it's very complicated. I mean, I've never made it. I know making NMN purely took some effort to scale it up and for some of the companies that have been doing this right now, there's like one major supplier out of China that pretty much everybody uses. But in terms of NAD, I don't think this is an industrial process. I can tell you it's not $700.

• 1:39:49Dr. Peter Attia?

  Yeah, I'm sure it's not. So if a person was going to supplement with one orally, do you think there's a case for NR being superior to NMN?

• 1:39:57Speaker 01

  I would say no. I would say take them both. If you're gonna do something and you want to a bit of an insurance, I did this for a while. I'm not doing it right now. Take 250 milligrams of each and you'll have a half a gram. You are in a relatively safe dose. Follow your homocysteine. If you are 60 or above, you could make the case this could be part of a stack. Although, this is the same thing that we see with so many of these supplements right now. Which one do you take? Which ones are beneficial? There's one little bit of a dark cloud linked to NAD supplementation is the demonstration that the SASP is actually dependent on NAD levels. And so when you are actually increasing

• 1:40:42Speaker 01

  NAD levels, you might be increasing these pro-inflammatory markers.

• 1:40:45Dr. Peter Attia?

  Let me make sure I understand why. Because the SASPs, which for folks listening, these are the soluble products made by the senescent cells that effectively are doing all the bad things that we don't want to see senescent cells doing. So now they are dependent on CD38 to some extent. So as CD38 goes up, they go up. And are you saying as you give more NR and more NMN?

• 1:41:10Speaker 01

  You might churn it up.

• 1:41:11Dr. Peter Attia?

  You might be churning up the SASPs?

• 1:41:13Speaker 01

  Yeah.

• 1:41:14Dr. Peter Attia?

  You finish your point and then I want to make a broader point.

• 1:41:16Speaker 01

  There's also some worry about the fact that supplementing with some of these precursors might also accelerate tumor growth. So this would not have an effect in you and I who don't have a cancer. But if it's someone out there who has an early form of a cancer, this could lead to an acceleration. This is something that's been shown in animal models that giving some pause to some people in terms of recommending this to be taken over by everyone.

• 1:41:41Dr. Peter Attia?

  The folks who make this have strenuously denied that there is any validity to those animal models that have suggested that. And some of this has been done in vitro as well, correct? I'm not very familiar with that literature. I saw, I remember seeing one study, it was very small. My take on it was, I guess if you had cancer, this might be a bad idea to take. But I didn't find it that convincing.

• 1:42:03Speaker 01

  I agree with you. It is a general consideration for our whole field of longevity research is better is the enemy of good, is something that was sort of drilled into me as I went through medical school. We have a term in French, which is sort of like therapeutic overdoing it, doing too much. There's such a thing as overdoing it for your patients. In this case, the whole longevity field is embracing a whole series of these interventions. I mean, it's not a week that doesn't go by that I don't see a new supplement being touted online and so on. And I read about all of them. The question is, which ones should you be taking? Which ones are actually risky? Which ones are not? And to me, this is part

• 1:42:45Speaker 01

  of the whole balance of the equilibrium that I'm trying to reach. There's something that really has a beneficial effect. You want to be on it as soon as possible. If not, why take the chance?

• 1:42:55Dr. Peter Attia?

  Yeah, that's the point I was going to make at the outset. You've said it so much better. Let's pivot a little bit to a couple of the things I want to chat about quickly. Let's talk about interleukin-11. Big trial last fall that looked at blocking interleukin-11, which is a molecule that's made by immune cells, plays an important role in inflammation. And this was done in mice, and those mice lived longer. What do you make of the study?

• 1:43:18Speaker 01

  I read the paper like you. I don't have sort of inside knowledge about, of course, when the paper came out, it was like interleukin-11. I mean, as an immunologist, you talk about one, interleukin-1, two, four, six, seven, but 11, never heard about it. It goes up to like 30. So I went and read the paper. It's an inflammatory marker. So again, it could be-

• 1:43:41Dr. Peter Attia?

  On par with 1 and 6?

• 1:43:43Speaker 01

  No, I would say probably not. So it came out of the left field, but it sort of makes sense in the context of what we know about the inflammatory response linked to aging. And maybe this is where I can add one point is- When we think about the chronic inflammation of aging, sort of inflammaging, it is both cause and effect. We talked about how the immune response helps you to protect yourself against the innate immune response, against pathogen as a first line of defense. The innate immune response also has another important role is that it recognizes damage, any kind of damage. If you cut yourself, if you have a wound inside of your organs.

• 1:44:24Dr. Peter Attia?

  Coronary artery, a coronary artery.

• 1:44:26Speaker 01

  A coronary artery. This will act, any kind of damage, unfolded proteins, there's all kinds of things. So the innate immune response will be triggered and will activate itself. So as we age and as damage slowly accumulates, because aging is a slow irreversible accumulation of damage, eventually your immune system responds to this by becoming chronically activated. And so the problem is that you might think, well, this is great because you're actually repairing all of this damage. The problem is the activation of the immune response by itself becomes problematic because these cells, macrophages, for example, are powerful tissue remodeler. The immune system in this case is Dr. Jekyll and Mr. Hyde.

• 1:45:10Speaker 01

  It's helping, but it's facing an unsurmountable amount of damage. And eventually its activation leads to an AD depletion. That's one of the things that it does, but many other things, stem cell dysfunction and mitochondrial dysfunction. So the whole idea here is that IL-11 might simply be, is one of the key markers of this chronically activated immune system. So this is not something I imagine you're going to give to a 20-year-old, but in someone who's getting really in the part where chronic immune activation is present, could really play an important role in the future. And what the paper showed was again in mice, but from what I understand is already an existing molecule. And they're actually, recently was contacted by a company that has another novel inhibitors

• 1:45:54Speaker 01

  of IL-11. You could imagine this to become part of the whole armamentarium that we have against aging.

• 1:46:01Dr. Peter Attia?

  And then how do you see playing that off something on the other spectrum? Because we're really trying to deal with two sides of this system. We want to tamp down the part that's overactive and we want to ramp up the part that's underactive. So we've got, basically, the only example we have over here is rapamycin. This one does this. And then we now have IL-11 inhibition, or use knockout mice, but block this. That did good things. So is this one of those things where you need to do both? By the way, maybe you have growth hormone over here as well.

• 1:46:31Speaker 01

  Yeah, IL-1 there also.

• 1:46:33Dr. Peter Attia?

  Yes.

• 1:46:33Speaker 01

  Anti-IL-1 as well.

• 1:46:34Dr. Peter Attia?

  That's right. Block IL-1, block IL-11, give growth hormone, give rapamycin. I mean, here's the problem. You get into this reductionist state, which is like the whole NAD world of NR and NMN. Hey, it sounds great, but what if there's unintended consequences we can't see? Like, even as much as I love thinking about this and want to do all of these things, I start to think, man, what is the probability we're going to get this right?

• 1:47:02Speaker 01

  I agree. The immune system is an incredibly tenuous system, which is in really delicate balance. So the balance is too much immunity. You might say, well, this is good. Protection against cancer, protection against microbes.

• 1:47:18Dr. Peter Attia?

  Right, but then you get autoimmunity.

• 1:47:19Speaker 01

  But then you get autoimmunity. Not enough immunity, well, you run the risk of being killed by pneumonia or some kind of infection.

• 1:47:27Dr. Peter Attia?

  But at least you don't have too much inflammation.

• 1:47:29Speaker 01

  Yes.

• 1:47:29Dr. Peter Attia?

  Yeah.

• 1:47:30Speaker 01

  So there's a very fine balance.

• 1:47:31Dr. Peter Attia?

  This is why I wish we had a dashboard. What are the biomarkers we can use for these things? Because we don't have this problem with blood pressure. We don't have this problem with thyroid hormone. We don't have this problem with so many things that we treat because we can measure what we care about.

• 1:47:48Speaker 01

  That's a good point. And the question is, the immune system is so complex, there's not going to be one single marker. My colleague David Furman is this thing called iAGE, which is an immune aging set of tests that you can actually conduct. That was the first attempt at trying to measure immune aging.

• 1:48:06Dr. Peter Attia?

  What do they actually measure? Is it all serum biomarkers?

• 1:48:09Speaker 01

  Yes, serum biomarkers and mostly cytokines.

• 1:48:12Dr. Peter Attia?

  Validated how?

• 1:48:13Speaker 01

  Been validated in clinical studies.

• 1:48:15Dr. Peter Attia?

  I-A, immuno-aging?

• 1:48:17Speaker 01

  Yeah, yeah. I-Age.

• 1:48:19Dr. Peter Attia?

  Oh, I-Age.

• 1:48:20Speaker 01

  Yes. So this was developed and pioneered by David Furman and Mark Davis. So David Furman is with us at the BACH. Mark Davis is still at Stanford.

• 1:48:29Dr. Peter Attia?

  I guess this brings us to clocks.

• 1:48:31Speaker 01

  Yes.

• 1:48:32Dr. Peter Attia?

  I don't even know if I have the energy to talk about this. Okay, where do you want to begin? There are so many of these things out there.

• 1:48:37Speaker 01

  Yes.

• 1:48:38Dr. Peter Attia?

  Some of them are commercially available. Some of them are just tools of research at the moment. Some of them aim to tell you an actual age, an actual number that represents your biologic age as opposed to your chronological age. Some of them don't aim to tell you that at all. They just want to tell you a rate of aging. Some of them look only at the epigenetic signature. In other words, they look directly at the methylation sequence. Others look at a host of markers, including some very simple serum biomarkers like glucose levels and vitamin D levels and things like that. So how do you make sense of all of those tools?

• 1:49:17Speaker 01

  Right now, we don't. First statement is they are not ready for prime time in terms of patient management. There are research tools.

• 1:49:26Dr. Peter Attia?

  Which is interesting because they're far outside of research labs at this point.

• 1:49:30Speaker 01

  Yes, they are available commercially. I've done the same thing. I don't remember who told. You told me someone actually, if it was Matt.

• 1:49:37Dr. Peter Attia?

  Matt Kabelin.

• 1:49:38Speaker 01

  Measured his clocks. I do the same thing. Actually, I measure them every three months.

• 1:49:42Dr. Peter Attia?

  It's just a scatter plot.

• 1:49:43Speaker 01

  It's a scatter plot in a way. You know, I'm between 25 and 68, which is, of course, I like the clock that show me to be young. But that being said, we know that we're learning. So we know that, for example, you alluded to the fact that they can vary the same clock. There's circadian variation, for example, five years. So your age can vary by five years using some of the clocks depending on when you measure.

• 1:50:07Dr. Peter Attia?

  What time of day?

• 1:50:08Speaker 01

  Yeah, what time of day? That's biology. That just tells you the epigenome is something that's highly dynamic. And so that's something as we learn. Obviously, the companies will encourage you to measure it, you know, to draw the blood always at the same time. Now, the whole field right now is pretty much focused, almost completely focused on DNA methylation. Steve Horvath has done beautiful work. I mean, it's really pioneering work identifying all this. And Morgan Levine and others have gone on. Dan Belsky at the. With Denadine Pace, which is another epigenetic clock that measures the pace of aging. By the way, I think this is probably my favorite because it really seems to be responding to interventions.

• 1:50:50Speaker 01

  If you change your diet or if you do something, you will see your pace of aging are changing. So I think that one to me seems more promising. We don't know really how to use these tools clinically. That's the problem. They're nice gadgets to buy. The companies are selling you supplements and then they're selling you the test with it. I don't know what to make of it. Personally, I think this is not ready for prime time. It's something that should be done in the future. Might become in the future.

• 1:51:17Dr. Peter Attia?

  Would you agree with my stern words on this? Because I've made a lot of enemies by saying that if as a consumer, you encounter a company that is selling you a test, especially a test that is not validated in any clinically meaningful way, and then in the same breath, selling you a supplement to fix the result of that test, you need to run.

• 1:51:44Speaker 01

  I agree.

• 1:51:45Dr. Peter Attia?

  I don't have the patience for that kind of behavior.

• 1:51:48Speaker 01

  Someone told me actually recently that one of these tests actually that you can measure, almost everyone who gets their result is low. And of course-

• 1:51:59Dr. Peter Attia?

  Low being good or bad in this test?

• 1:52:00Speaker 01

  It's bad.

• 1:52:01Dr. Peter Attia?

  Bad, yeah.

• 1:52:01Speaker 01

  It's insufficient. The next step is the recommendation. You have to buy this supplement to solve the problem. So yes, again, it's the same thing with the Sartreans and the NAD. Let's not throw out the baby with the bathwater. There is a whole series of these players. I'm not disputing their honesty or their good intention. From what I've seen, I think it's too early.

• 1:52:23Dr. Peter Attia?

  And what do you think is the biggest problem? Is the biggest problem the biologic noise in the system? Which means even if you had the absolute perfect tool to measure and you knew exactly what to measure, the movement of that thing is so great that the probability that you're capturing a meaningful value is irrelevant. In other words, imagine that there's a variable that moves like this, but on the small- All level, it's moving like this. I'll give you an example. Imagine you were measuring heart rate, but you could only sample it milliseconds at a time. And what you were actually measuring was heart rate variability instead of heart rate. It would be useless. It's too noisy.

• 1:53:04Speaker 01

  I agree.

• 1:53:05Dr. Peter Attia?

  Do you think that's the problem?

• 1:53:05Speaker 01

  No, I don't think that's a problem. I'll speak personal experience. I work with true diagnostic. They use the epic array and you get not one clock, you get dozens. So I get all of them. And they tend to be reproducible, you know, every three months unless I make some interventions. But in general, there is some consistency. I'm not the only one who's seen this. So my advice, if you really are determined to use them, use all of them. They all are different mirrors of your reality. The problem of the methylation clocks is that there's a very tenuous link between the change of methylation at any given site and the biology. Typically, the clock, each clock would roll out on about 500 different methylation sites.

• 1:53:50Speaker 01

  But they're not attached to a specific gene, so you don't really know what it means.

• 1:53:54Dr. Peter Attia?

  But how are they even doing that? They're not measuring with point arrays.

• 1:53:58Speaker 01

  They do this with arrays.

• 1:53:59Dr. Peter Attia?

  They're doing this with an array?

• 1:54:01Speaker 01

  About 20 million methylation sites that they're assessed. But each clock uses a subset, four or 500.

• 1:54:07Dr. Peter Attia?

  Sorry, just to be clear, you're saying they're actually measuring point of methylation? Okay.

• 1:54:13Speaker 01

  Yes. They quantify in the level of methylation at each of these sites. The problem with the clocks is also where do you obtain them from? Typically, blood, as I mentioned, it's a heterogeneous compartment. As you age, for example, you know that your fraction of naive T cells decreases down to close to zero if you're 80 years old, your memory T cells increase. So we did a very simple experiment. We sorted all of these different T cell subsets, memory, naive, central memory, temra, determinedly differentiated, and measured their epigenetic age using

• 1:54:49Speaker 01

  Several of the clocks, twenty to twenty-five year difference.

• 1:54:53Dr. Peter Attia?

  Between?

• 1:54:54Speaker 01

  Between the naive and the central memory T cell.

• 1:54:57Dr. Peter Attia?

  In the right direction, the direction you would predict.

• 1:54:59Speaker 01

  Yes, the naive are much longer.

• 1:55:01Dr. Peter Attia?

  Yeah, that's somewhat interesting.

• 1:55:03Speaker 01

  That was really interesting for me because it means also any conditions where you see a shift in the relative proportion of these cells. For example, you get an acute COVID infection. What happens? You have a massive expansion of your memory T cells. So it looks like you're going to, and then you sample, and given that these cells look much older than the other ones, you're going to look like you're aging. And there's a whole literature that talks about accelerated aging and rheumatoid arthritis, and COVID, and HIV, all of these conditions that are all associated with chronic immune activation. So that's another confounding variable. So what we did to do this with a student in a lab, we made a new clock in

• 1:55:46Speaker 01

  which we eliminated all of these methylation sites that are linked to differentiation. Okay, so now this clock that we've done does not vary, actually, as a function of the types of cells that are in the blood. As a T cell goes from being a naive T cell to being a memory T cell, to being a temra, the methylation patterns change. That's part of the epigenetic regulation. So we eliminated all of those sites, made a new clock called intrin clock, which actually is impervious to your level of immune activation. And what's interesting is that that clock doesn't change anymore during COVID. It doesn't change very little during HIV. It doesn't change during a whole series of conditions where people

• 1:56:27Speaker 01

  have talked about aging acceleration, including the story that we talked about earlier on growth hormone.

• 1:56:35Dr. Peter Attia?

  What does change it then?

• 1:56:36Speaker 01

  What does change it? Cancer, senescence, which is really interesting.

• 1:56:42Dr. Peter Attia?

  What about short-term interventions that might be beneficial? So if you took an individual who Is insulin resistant? And you put them on a GLP-1 agonist? And three months later, they're 20 pounds lighter and their insulin resistance has resolved? How does that change on the clock?

• 1:56:58Speaker 01

  Would not be able to tell you specifically for individual clocks, but Dan Belski's Denitin Pace clock is the one that repeatedly people have shown seems to be responding to interventions, which is the two qualities that you want in a clock is one to be predictive and the other one to be predictive of ultimate income, sort of life expectancy or the occurrence of disease, but also you want it to be modulatable, responsive.

• 1:57:27Dr. Peter Attia?

  And reproducible.

• 1:57:28Speaker 01

  And reproducible, yes. Reproducible, I think, is more a question of the laboratory that's doing it, so there are no-

• 1:57:35Dr. Peter Attia?

  But also potentially the biologic noise still.

• 1:57:37Speaker 01

  Exactly.

• 1:57:38Dr. Peter Attia?

  So biologic noise and laboratory conditions speak to reproducibility. I agree with what you said. I mean, I've often made this case when people ask me about clocks is my gripe with the age clock, so again, the pace clock is different because it's just trying to give you a rate of aging, and I agree with you, I think there might be more there. But these clocks that spit out, hey, Eric, congratulations, you're 25. I say to someone who says, isn't that wonderful? I say, maybe, but do you actually believe that you're 68? You're 68 and your clock said you're 25. Should I expect you to live another 55 years?

• 1:58:13Speaker 01

  Yes.

• 1:58:14Dr. Peter Attia?

  In other words, is it a better predictor of future life than chronological age? And the answer is, to my knowledge, no. There is no clock that has a better ability to predict lifespan than chronological age does. And until that's the case, I worry that the biologic clocks are creating a bit of a distraction, at least this subset of clocks, and that we maybe ought to focus better on clocks where the readout state is more about, is this intervention good or bad? Or is this a net positive intervention or a net negative intervention?

• 1:58:53Speaker 01

  I agree. As we mentioned earlier, the field initially focused on the epigenetic clocks, because this is Steve's, Horvath's pioneering work. So it got everybody to start thinking, we can generate these tools. But the field is now moving into proteomics clock.

• 1:59:08Dr. Peter Attia?

  So what makes up Dan's clock?

• 1:59:10Speaker 01

  Dan is a methylation.

• 1:59:12Dr. Peter Attia?

  It's also methylation. Why do you think it's doing a better job than maybe Horvath's clock at the moment?

• 1:59:18Speaker 01

  Typically, it really depends on what the variable, what the cohorts, what the question was. I don't know. I mean, I think Dan's is the only one that's doing it in this way. Why is it working better? They're just looking at it in a completely different way.

• 1:59:32Dr. Peter Attia?

  How much is AI facilitating this at this point?

• 1:59:35Speaker 01

  Machine learning is the key instrument. Essentially, what these clocks are is regression analysis on to, start with a variable, which is your age, and you regress each methylation site onto the age. You do this on enough people of different ages, you find an average.

• 1:59:52Dr. Peter Attia?

  I wonder if that's the wrong way to do it. Wouldn't it be better to get biobanked data? And instead of mapping it onto age, map it onto number of years remaining in life? Because if you'll know that in a biobank.

• 2:00:05Speaker 01

  They've done this. They've done this.

• 2:00:06Dr. Peter Attia?

  Okay.

• 2:00:06Speaker 01

  They've done this in terms of life expectancy. They've done this in terms of morbidity. So this is like the third and fourth generation of these clocks now are looking at regression. The initial one.

• 2:00:18Dr. Peter Attia?

  Was just chronological.

• 2:00:19Speaker 01

  Yeah, and Steve used to go around saying my correlation coefficient is 99. And I was like, well.

• 2:00:24Dr. Peter Attia?

  That's because that's what you built it on.

• 2:00:26Speaker 01

  Yeah, exactly. I can look at a calendar. I don't need an epigenetic clock to tell me how old I am. But the next generation clocks actually had a bigger spread. Of course, you have an average.

• 2:00:36Dr. Peter Attia?

  That's right, because they started to build it on a different variable.

• 2:00:39Speaker 01

  Exactly. So what really excites me right now is the whole idea that the field is moving on to the next stage, which is non-epigenetic clocks. Because I'm still frustrated as a biologist trying to understand what are these clocks?

• 2:00:52Dr. Peter Attia?

  It should be everything. It doesn't make any sense to me that we wouldn't look at the metabolome, the proteome, and the epigenome. There's no excuse today with the compute power not to do that.

• 2:01:01Speaker 01

  We have clocks based on fundus, we have clocks based on skin, we have clocks based on facial recognition. So the clocks are going to be measured using dozens of different biological variables. Any biome, small company in the Bay Area is using it, the tongue, a tongue picture, the old doctor looking at your tongue. So you can actually use machine learning to recognize patterns of discoloration. And another exciting really story was, I don't know if you're familiar with a Tony Wiskore's paper using proteomics. He has shown, for example, proteome in plasma changes throughout life. Pretty dramatic matter, which is really completely mind boggling for me to see that you can be so different as you age in terms

• 2:01:46Speaker 01

  of your whole blood proteome.

• 2:01:48Dr. Peter Attia?

  Why? If the epigenome is changing, then gene expression is changing. If gene expression is changing.

• 2:01:53Speaker 01

  No, no, you would.

• 2:01:55Dr. Peter Attia?

  Yeah, yeah, yeah, it's okay.

• 2:01:56Speaker 01

  But that it would change to such a degree. Tony has a beautiful slide which shows all of the proteome in the blood and how the colors changed across.

• 2:02:06Dr. Peter Attia?

  And do you think that most of those changes are post-translational?

• 2:02:09Speaker 01

  No, most of them are probably expression level.

• 2:02:11Dr. Peter Attia?

  It's expression?

• 2:02:12Speaker 01

  Yeah, it's expression.

• 2:02:13Dr. Peter Attia?

  Okay.

• 2:02:13Speaker 01

  People are building transcriptomics clock. And so Tony now has a study that is, I believe, in press or coming out soon, where they've gone back using this proteomics clock. And they've done this on a UK biobank, more than 40,000 different people. And this is the study I, we started this discussion on identifying, what Tony did was actually remarkable. He looked at each of these proteins that are in the blood and selected some that were predictive to be coming from unique organs. Imagine what you know about how you measure at troponin for heart attack. So they did this, they went and looked in every single organ and say,

• 2:02:54Speaker 01

  okay, what proteins are specific of this organ and which ones actually can be measured into the plasma. And using this, they were able to generate what they call an organ specific clock. Simply from a blood draw, they're able to really determine, do you have a frailty point when I look at you? Is there like suffering happening?

• 2:03:13Dr. Peter Attia?

  And this is Tony's work through the proteome?

• 2:03:15Speaker 01

  Tony Wiskore, it's a new startup called Viro. For disclosure, I've joined the board of this company, but I I only joined the board because I was really excited about what they're trying to do. And I think it really brings a whole new dimension to these predictive biomarker, which is more aligned to what you and I have seen as physicians. Got a simple minded, as the protein is released into the blood, it shouldn't be there. It might be indicating some suffering and I discussed with some colleagues who have used this clocks and have identified some abnormal aging in a unique organ, only to go back and find that there was indeed one problem without going into what the issues were.

• 2:03:57Dr. Peter Attia?

  The reason I tend to be a slow adopter of these things is even if that's the case, the question is how much noise is in the system? I go and do that test on a patient and it comes back and says, oh, my God, there's something wrong with your liver. Your kidney is a bit too old, you're this, you're that, you're this, you're that. So I have two fundamental questions. The first is, could I have figured that out another way? So if it's telling me your liver is angry or something's wrong with your liver, how do your transaminases look? If it's telling me something's wrong with your kidney, could I have picked that up on a urinary analysis, looking at creatinine clearance or cystatin C or something else? In other words, is it giving me information that I can get elsewhere in a more reproducible, more validated fashion?

• 2:04:39Dr. Peter Attia?

  The second thing is, let's say it tells me seven things are not perfect. And by the way, everything looks perfect. I have my standard assays, everything looks awesome. This test says, oh, my God, these six or seven things are problematic. And I go poking around, poking around, poking around, and I find out one of them is indeed not working, but the other six were perfectly fine. So now we have this huge false positive situation.

• 2:05:03Speaker 01

  That's that's a whole MRI.

• 2:05:05Dr. Peter Attia?

  Yeah, exactly. It's the same problem we have with cancer screening, which is buyer needs to beware of the Pandora's box you open. And at least with MRI, you're dealing with imaging. But this sounds like exciting and yet it's a bit of a black box.

• 2:05:19Speaker 01

  Agreed.

• 2:05:19Dr. Peter Attia?

  Where it's going to spit out, oh, my God, there's something. Wrong with your left testicle and what do I need to do, you know?

• 2:05:25Speaker 01

  That being said, I think the assays are generated in a way that there are multiple. It's not like one single protein like a triple myosin. We know that's a clear indicator. There's something cell death in terms of your heart. In this case, the clocks are generated in a way that there are multiple sentinels for each organ. Many. The story I was talking about, early days, okay? We totally agree with this. It's a startup. I think they will deploy it. And obviously it's going to take again, a group of physicians who are able to look at these tests. This is what research is. This is what startup, you know, can't blame them for trying because I think it has a potential, for example, to highlight a frailty point, which is in aging research to me is really critical. You could have the best mind and the best heart in the world.

• 2:06:10Speaker 01

  If something else is going to fail that you are completely unaware of, you want to know as soon as you can. My prediction is I'll share the paper with you if you're interested in looking. It's quite exciting in terms of where this is leading, but I agree with you early days.

• 2:06:24Dr. Peter Attia?

  Yeah, I will probably maintain a shockingly high degree of skepticism and probably enjoy some experimentation with it. But again, my, my experience in the real world is that that's just not how it works. There aren't people walking around that are insanely remarkably healthy, where everything looks amazing. But they have some time bomb they don't know about, with the exception of a few things. I'm not sure it would pick up. For example, cancer is always that thing. And of course, there's an entire field of medicine that's going around with liquid biopsies. That's exactly trying to solve that problem. You could reword the liquid biopsy industry through the lens you said, which is it's looking for that weakest link, which in this case is the earliest signs of cancer.

• 2:07:05Speaker 01

  And it could be that a cancer will manifest itself also in local organ suffering. And again, leaching, it might actually point along with a liquid biopsy that tells you you have some cancer cell. It might tell you, it might point you to one place where actually this is actually happening.

• 2:07:21Dr. Peter Attia?

  Yeah, it's interesting.

• 2:07:23Speaker 01

  The case that I've made about MRI is the same. I have a whole bunch of physician friends. I get a yearly MRI and they tell me, why do you do this? I say, well, because I would rather know. He said, well, you're going to find all kinds of things. I said, we did find something. I had a tumor behind my jaw and a mass. It was not a tumor, but it took me six months of worrying

• 2:07:44Dr. Peter Attia?

  That's right.

• 2:07:45Speaker 01

  about what it was and decided not to biopsy anything. My sense of all of this is that these are novel ways to practice medicine.

• 2:07:53Dr. Peter Attia?

  I'm criticized heavily for being too much on the forefront of doing that, but probably not nearly as far as some. At the end of the day, I think about every time you do a test, one, you never do a test unless you're willing to act on an outcome or you have a sense of how an outcome will change your behavior. We don't order tests for the sake of information. We order tests to make decisions. Therefore, you must, at a minimum, understand the full suite of outcomes that can come from the test and how many of them will pose huge trouble for you. 20% of my patients opt not to do whole body MRI.

• 2:08:32Speaker 01

  Yes.

• 2:08:33Dr. Peter Attia?

  And I fully endorse that decision. And I try to talk patients out of it. I really try to highlight how many times we find thyroid nodules that we have to put needles into that ultimately end up being nothing. And all we do is subject them to that risk and

• 2:08:47Speaker 01

  The anxiety.

• 2:08:48Dr. Peter Attia?

  the anxiety that comes along with it. So I'm eager to look at this because I do think that the proteome offers a lot, but I'm always worried about going a little too far on the clinical implication of a test.

• 2:08:58Speaker 01

  I'm with you in terms of being careful. I view this as another attempt. For example, we talked about the data showing that the two organs that appear to be rate limiting in terms of aging, the immune system and the brain, that came out of that story. That's actually the title of the paper essentially. That identifies the brain and the immune system. So they, they have a whole series of immune markers that are predictive of some degree of immune activation and so on.

• 2:09:26Dr. Peter Attia?

  Well, Eric, there's a lot of other things I wanted to chat about, but I think what we'll do is we'll have you come back out to Austin for another day of driving at Cota, and then we'll justify it by doing another podcast where we dive deeper into some of these topics. We really take advantage of the fact that we have the best race course in the country here in our backyard. So I think you're gonna have fun tomorrow and

• 2:09:45Speaker 01

  Good.

• 2:09:46Dr. Peter Attia?

  You'll be like, "Let's come right back and do it again every month."

• 2:09:48Speaker 01

  I'm looking forward to this.

• 2:09:50Dr. Peter Attia?

  Thank you, Eric.

• 2:09:51Speaker 01

  Thank you.

• 2:09:52Dr. Peter Attia?

  Thank you for listening to this week's episode of The Drive. Head over to peterattiamd.com/shownotes if you want to dig deeper into this episode. You can also find me on YouTube, Instagram, and Twitter, all with the handle PeterAtiaMD. You can also leave us a review on Apple Podcasts or whatever podcast player you use. This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute

• 2:10:36Dr. Peter Attia?

  for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice from any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. Finally, I take all conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit peterattiamd.com/about, where I keep an up-to-date and active list of all disclosures.